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CHAPTER I 
 
INTRODUCTION 
 
Since the onset of modern genetics, mouse (Mus musculus) has provided a 
model for understanding mammalian gene functions and human diseases. The 
development, physiology and diseases of mice most resemble those of human 
beings and 99% of mouse genes have human orthologs (Bedell, Jenkins et al. 
1997; Cox and Brown 2003). Classical genetic studies, so called “forward 
genetics”, start with an inheritable trait and then characterize the mutation(s) 
responsible for the trait. Mouse embryonic stem cell technology enables “reverse 
genetics” in which gene functions are studied first by creating a mutation in a 
specific gene and then determining the phenotypes of mice bearing the mutation 
(Thompson, Clarke et al. 1989). Mutations may be induced in stem cells by 
homologous recombination that targets specific gene sequences (Doetschman, 
Gregg et al. 1987) or by gene entrapment that generates large collections of 
randomly mutagenized stem cell clones from which clones with mutations in 
specific genes of interest are selected for transmission into the mouse germline 
(von Melchner and Ruley 1989; Skarnes, Moss et al. 1995; Hicks, Shi et al. 
1997). Mutant mouse models generated by gene targeting and gene entrapment 
have been used to delineate in vivo functions of large numbers of genes. The 
sequencing of the human and mouse genomes has identified most of the 25,000 or 
so genes required to specify mammalian organisms and has marked the beginning 
of the post-genome era of biomedical research (Lander, Linton et al. 2001; 
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Venter, Adams et al. 2001; Waterston, Lindblad-Toh et al. 2002). Efficient 
mutagenesis strategies are required for functional studies of the many genes now 
characterized at the nucleotide level. My thesis will describe studies on deficient 
mouse models of the Ssrp1 and Pfdn1 genes, which were generated by 
conventional gene targeting and gene entrapment, respectively. This introduction 
will provide a brief review of major mutagenesis strategies and provide 
background and rationale for my thesis research. 
 
Functional genomics in the post-genome era  
A draft sequence of the human genome was completed in 2001 (Lander, 
Linton et al. 2001; Venter, Adams et al. 2001), while the mouse genome was 
sequenced in 2002 (Waterston, Lindblad-Toh et al. 2002).  Now functional 
analysis of these 25,000 or so genes in the human and mouse genomes has 
become the major challenge. The Comprehensive Knockout Mouse Project 
Consortium was founded based on the premise that knockout mouse models 
should be made in a large scale, eventually covering all mouse genes. However, 
published knockouts correspond to only ~15% of the mouse genes (Austin, Battey 
et al. 2004). Therefore, generating knockouts for the remaining 85% of the genes 
necessitates efficient means for large-scale mutagenesis.  
The following sections will briefly describe various mutagenesis strategies 
and their potential application in comprehensive analysis of mammalian gene 
functions. 
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Chemical mutagenesis 
Chemical mutagens induce mutations at frequencies of 1.3x10-5 ~1.5x10-3 
per locus and produce relatively specific spectrums of DNA sequence alterations. 
For example, ethyl-nitrosourea (ENU), an alkylating agent, a carcinogen and a 
super-mutagen (Russell and Montgomery 1982), induces single nucleotide 
transversions and transitions in the spermatogonial lineage of treated males. 
Through crosses and backcrosses of a treated male with wild type mice, dominant 
phenotypes and recessive phenotypes were examined among the immediate or 
later offspring, respectively (Bode 1988; Balling 2001). ENU mutagenesis 
screening of mutations on certain regions could take advantage of balancer 
chromosomes (Rinchik 1991). A balancer chromosome contains an inverted 
region that suppresses crossing over during mitotic recombination, a dominant 
genetic marker such as a coat color gene, and a recessive genetic marker that 
contributes to the death of mice homozygous for the balancer. Mice containing a 
balancer chromosome and an ENU-induced mutation on the corresponding region 
of a wild type chromosome could be selected by the coat color from offspring of 
the ENU-treated stud.  
As a forward genetics approach, ENU mutagenesis allows large-scale 
screening for phenotypically important mutations. Moreover, different ENU-
induced mutations in the same gene could lead to differing phenotypes, providing 
tools for detailed study of gene functions (Balling 2001). However, the mutation 
must first be mapped and then isolated by positional cloning (Beier and Herron 
2004). Moreover, extensive back breeding required to analyze recessive mutations 
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is logistically demanding and limits the use of chemical mutagenesis for genome-
wide analysis of gene function (Justice 2000; Balling 2001).  
 
The impact of mouse embryonic stem cell technology 
Mouse embryonic stem (ES) cell technology heralded a new era of mouse 
genetics. Derived from the inner cell mass (ICM) of pre-implantation mouse 
blastocysts (Evans and Kaufman 1981), ES cells can be cultured in vitro retaining 
pluripotency and can contribute to the germline of chimeras when injected into 
blastocysts (Bradley, Evans et al. 1984). Offspring of the chimeras can be 
intercrossed to analyze biological consequences of recessive mutations. The 
ability to transmit a mutation introduced into cultured ES cells into mice paved 
the way to analyze gene functions following gene targeting by homologous 
recombination, large-scale mutagenesis by gene entrapment, as well as chemical 
mutagenesis in ES cells (Chen, Yee et al. 2000; Vivian, Chen et al. 2002).  
 
Homologous recombination and gene targeting 
Genomic DNA fragments can be engineered and introduced into a 
mammalian cell to recombine with the endogenous homologous sequence. This 
process, termed homologous recombination, was first reported in mammalian 
cells in 1985 (Smithies, Gregg et al. 1985). The first successful targeting in mouse 
ES cells, which disrupted the hypoxanthine-guanine phosphoribosyl transferase 
(HPRT) gene, was reported two years later (Doetschman, Gregg et al. 1987). 
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Germline transmission of a targeted HPRT allele in ES cells was first reported in 
1989 (Thompson, Clarke et al. 1989).  
A typical procedure of gene targeting starts with the construction of a 
targeting vector containing a selectable marker gene (and a negative selection 
marker in some designs), and flanking genomic sequences that are homologous to 
the desired chromosomal integration site (van der Weyden, Adams et al. 2002). 
The targeting vector is electroporated into ES cells, which is subsequently 
cultured in selective media (such as G418 for neomycin resistance). The resistant 
clones are screened for the presence of the desired recombinant allele by Southern 
blot or PCR analysis. Selected ES clones are injected into blastocysts (3.5 day 
embryos), which are then transferred to the uterus of a foster mother. Since 
targeted ES cells are male and are of 129 background, chimeric male pups with a 
high percentage of agouti coating have relative high possibility of germline 
transmission. These chimeras are crossed with wild type females to determine the 
efficiency of germline transmission. The resulting F1 heterozygotes can then be 
intercrossed to generate homozygous mutants (Fig. 1.1). As such, homologous 
recombination in ES cells, in concert with germline transmission, provides 
powerful means to generate gene deficient mice and therefore reveal gene 
functions in vivo.  
Gene targeting studies can be enhanced by the use of recombinase systems 
such as Cre/loxP from the bacteriophage P1 (Lakso 1992; Orban 1992; Gu 1994), 
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B 
Blastocysts implanted in 
a foster mother may give 
rise to chimeric pups.  
Mice carrying the 
targeted allele can be 
bred from offspring 
of the chimera. 
Correctly targeted ES 
cells identified by 
Southern blot or PCR 
analysis are injected into 
blastocysts. 
ES cells are transfected 
or electroporated with 
the targeting vector and 
cultured in selection 
media. 
Mutant allele 
Wild type allele 
Targeting vector 
A 
Figure 1.1. Schematic of gene targeting strategy. 
A. Homologous recombination between the targeting vector 
and wild type gene generate the mutant allele.  
+:  Positive selection marker. -: Negative selection marker. 
B. Targeted mouse ES cells and germline transmission. 
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 and Flipase/FRT from the budding yeast S. cerevisiae (Farley, Soriano et al. 
2000; Rodriguez, Buchholz et al. 2000). The resulting strategy, namely 
“conditional targeting”, provides a means to study in vivo gene functions in a 
temporal and/or tissue-specific manner.   
To date, gene targeting has contributed to unprecedented insights in gene 
functions and generated many disease models (Zambrowicz and Sands 2003). 
However, since the process of constructing a targeting vector and screening 
desired clones requires adequate knowledge of the gene structure and significant 
effort, some knowledge about the function of the target gene is required to 
provide a rationale for the knockout (Misra and Duncan 2002). Targeting attempts 
are often avoided for many genes that have been characterized only at the 
nucleotide level and for genes that are possibly required for the viability of mice 
or cells. Nevertheless, the Mouse Knockout Project validates the idea that all 
genes should be evaluated (Austin, Battey et al. 2004). Therefore, disrupting 
essentially all genes in the genome requires gene targeting and the 
complementation of strategies that are more efficient and economic. 
 
Gene trapping 
Taking a middle path between random and specific mutagenesis described 
above, gene entrapment randomly alters genes in ES cells. The gene trap is 
essentially a drug resistance gene incorporated into one or more exons that are 
allowed to integrate randomly throughout the genome. The appropriate selection 
generates cell clones in which the entrapment vector has inserted into endogenous 
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genes. The mutagenized ES clones are used to generate mutant mice usually 
following selection or screening to select clones with mutations in specific genes 
based on sequence analysis or expression patterns (Evans 1998; Stanford, Cohn et 
al. 2001) (Figure 1.2). 
Entrapment vectors include the enhancer trap, promoter trap, gene trap and 
polyA gene trap. Enhancer traps contain an autonomous minimal promoter and 
lacZ reporter gene, which is expressed when the vector inserts in regions 
influenced by cis-acting enhancer elements (Kothary, Clapoff et al. 1988). Since 
enhancers can act over large distances, a high proportion of inserted enhancer 
traps are expressed without disrupting cellular genes, thus undermining their use 
for insertional mutagenesis (Gossler, Joyner et al. 1989; Korn, Schoor et al. 
1992). 
Promoter trap vectors basically consist of a promoter-less reporter gene 
and/or selection marker. Insertion of the vector into an exon gives rise to a fusion 
transcript consisting of upstream exons of the occupied gene and the 
reporter/selection marker, thus selecting for highly mutagenic events (von 
Melchner and Ruley 1989; Reddy, DeGregori et al. 1991). However, by design, 
entrapment by promoter traps is limited to genes that are transcriptionally active 
in ES cells. In addition, exon definition frequently activates cryptic 3’splice sites 
which, when used in conjunction with the polyA site inserted by the vector, allow 
the selection/reporter gene to be expressed as a 3’ terminal exon. Alternative 
splicing of the cryptic splice sites may result in hypomorphic mutations 
(Osipovich, White-Grindley et al. 2004; Osipovich, Singh et al. 2005). 
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Figure 1.2. Gene entrapment vectors. 
Representative enhancer trap (A), promoter trap (B), gene trap 
(C) and polyA gene trap (D) vectors with a lacZ reporter and 
neomycin resistance gene (neo) selecting for insertion events in 
(gene traps) or near (enhancer traps) cellular gene. Major 
functional elements are labeled; active promoters are indicated 
with arrows.  
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Gene trap vectors contain a splice acceptor and a promoter-less gene that 
is typically a reporter and selection marker (Gossler, Joyner et al. 1989). Designed 
to utilize endogenous promoter and enhancer elements by inserting into the intron 
of a trapped gene, gene trap vectors give rise to a fusion transcript of upstream 
exons and the reporter/selection marker, which can be used to identify trapped 
genes by rapid amplification of 5’ cDNA ends (5’RACE) (Frohman 1988). 
Although the trapping efficiency is relatively high, the mutagenicity of gene traps 
is sometimes inhibited by alternative splicing (McClive, Pall et al. 1998).  
PolyA gene traps consist of a mutator cassette consisting of a 3’ terminal 
exon and a polyA trap cassette that contains an autonomous promoter and a 
selection marker flanked by a splice donor site. The insertion into an intron 
typically leads to two fusion transcripts. One corresponds to the upstream exons 
of the disrupted genes that splice to the mutator cassette; the other contains the 
selection marker spliced to the downstream exons (and polyA) of the occupied 
gene. Since the selection marker is expressed from an autonomous promoter, 
polyA gene traps can disrupt genes not expressed in ES cells. However, polyA 
gene traps preferentially insert in the last intron of the trapped gene, which allows 
fusion transcript to avoid nonsense-mediated decay. This can position the inserted 
gene trap downstream of the protein coding sequences without disrupting the 
expression of the occupied gene. (Baker and Parker 2004; Maquat 2004; 
Osipovich, Singh et al. 2005; Shigeoka, Kawaichi et al. 2005). 
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In general, gene trapping strategies provide gene-driven approaches that 
efficiently generate large-scale random mutations of genes. Moreover, gene 
entrapment can be coupled with DNA sequencing screens, as “tagged sequence 
mutagenesis”. Gene entrapment is relatively economic in generating knockout 
models of large numbers of genes, including those that would be selected for 
mutagenesis by gene targeting. Therefore, gene trapping complements 
conventional gene targeting in the genome-wide knockout project. 
 
Transposon-based mutagenesis  
In addition to ENU mutagenesis, transposon-mediated mutagenesis shows 
promise for phenotype-driven mutagenesis screens (Miskey, Izsvak et al. 2005). 
A naturally occurring mobile genetic unit, the transposon, typically consists of 
flanking terminal inverted repeats (IRs), which contain binding sites for a 
sequence-specific transposase; and a transposable element (PE), which encodes 
the transposase, the only protein required for the transposon to move from one site 
in the genome to another (Izsvak, Ivics et al. 2000). Transposon-mediated 
mutagensis has been widely used in prokaryotes, Drosophila and Zebrafish. A 
synthetic transposon, Sleeping Beauty (SB), is active in mammalian cells and used 
for insertional mutagensis (Luo, Ivics et al. 1998; Carlson, Dupuy et al. 2003). 
Unlike chemical mutagenesis, transposon-induced mutations contain molecular 
tags that allow genes responsible for specific phenotypes to be easily identified. 
However, new transposon inserts occur mostly in close range of the original site, 
while transposons in general have limited packaging capacity (Dupuy, Fritz et al. 
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2001; Dupuy, Clark et al. 2002; Drabek, Zagoraiou et al. 2003). Practical use of 
transposon mutagenesis in mice will require new vectors that are not affected by 
these limitations. In this regard, the newly described piggyBac (PB) looks quite 
promising (Ding, Wu et al. 2005).  
 
RNA interference  
Recently, RNA interference techniques have greatly impacted genetics 
and cell biology in plants, Drosophila, C. elegans, and gradually also in 
mammalian cells and organisms (Geley and Muller 2004).  In short, a 21nt RNA 
duplex called small interference RNA (siRNA), is recognized by RNA-induced 
silencing complex (RISC) when introduced into cells, and RISC activity degrades 
cellular RNA homologous to the siRNA sequence, thus repressing function of the 
corresponding gene (Agami 2002).  To achieve long-term knockdown effects in 
mammalian cells, vector systems have been developed that use RNA polymerase I 
or III promoters to express siRNA, either from short hairpin RNAs (shRNA), or 
from two complementary short RNA strands (Brummelkamp, Bernards et al. 
2002; Paddison, Caudy et al. 2002; Paddison, Caudy et al. 2002; Yu, DeRuiter et 
al. 2002). A transgenic knockdown mouse was first reported in 2002, with 
ubiquitous knockdown of EGFP expression (Hasuwa, Kaseda et al. 2002), and 
knockdown of endogenous targets was soon achieved using retroviral and 
lentiviral vectors (Hemann, Fridman et al. 2003; Rubinson, Dillon et al. 2003).  
In principle, RNAi could provide a fast and economic alternative to 
existing mutagenesis strategies. However, a microarray gene profiling study 
 13
revealed considerable off-target gene regulation in cells transfected with a 
silencing siRNA (Jackson, Bartz et al. 2003). In addition, shRNA was recently 
reported in some mammalian cells to induce interferon responses, which was 
previously assumed to be induced only by longer dsRNA (Bridge, Pebernard et al. 
2003). Therefore problems with knockdown specificity and interferon response 
limit the use of current RNA interference techniques for genetic studies in mice. 
 
Historical context and rationale of the thesis project  
Among the major mutagenesis strategies described above, gene targeting, 
in combination with gene trapping, appeared to be efficient strategies to generate 
knockout models for essentially all genes in the mouse genome. My dissertation 
describes the analysis of mice with mutations in Ssrp1 and Pfdn1, generated by 
conventional gene targeting and gene trapping, respectively.  
Chapter II describes the targeting of Ssrp1, which encodes the high-
mobility-group (HMG) protein SSRP1/T160, a member of a conserved 
chromatin-remodeling complex (FACT/DUF/CP). SSRP1/T160 was first reported 
to bind cisplatin-DNA adduct (Bruhn, Pil et al. 1992), and a V(D)J recombination 
signal sequence (Shirakata, Huppi et al. 1991). Cisplatin, a chemotherapeutic 
agent, produces cisplatin-DNA adducts and kills rapidly growing cancer cells by 
triggering G2 cell-cycle arrest and apoptosis (Cohen and Lippard 2001). The role 
of the p53 tumor suppressor in this process is well established (Lowe, Ruley et al. 
1993). By producing cells and mice deficient in SSRP1, I had hoped to analyze 
cellular responses to cisplatin-induced DNA damage, and to delineate the 
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underlying molecular mechanism for the cisplatin-induced apoptosis. In addition, 
Ssrp1 deficient cells could be used to study the involvement of SSRP1 in the 
V(D)J recombination process, which was suggested by its binding ability to the 
V(D)J recombination recognition sequence. Moreover, the two processes might 
be fundamentally related, given the involvement of proteins involved in double 
strand break repair in V(D)J recombination, such as Ku70, Ku80, DNA ligase IV 
and XRCC-4 etc. (Ramsden and Gellert 1998; Nick McElhinny, Snowden et al. 
2000). 
My own work determined that Ssrp1 is required for cell viability (Cao, 
Bendall et al. 2003).  During the course of these studies, Ssrp1 was found to be a 
highly conserved component of the chromatin remodeling complex FACT 
(facilitating chromatin transcription), involved primarily in transcription 
elongation (Orphanides, Wu et al. 1999). The binding of SSRP1 to cisplatin 
adducts and RSS may therefore reflect a conformation specific DNA binding 
activity that is not directly involved in cellular responses to cisplatin-induced 
DNA damage or V(D)J recombination. Furthermore, the requirement for Ssrp1 in 
cell viability precluded the planned studies using Ssrp1 deficient cells. 
 
Chapter III describes the gene entrapment of Pfdn1 gene, which codes for 
the first subunit of molecular chaperone prefoldin. In vitro biochemical and 
structural studies established prefoldin as a co-chaperone of chaperonin TRiC 
(Tcp-1 ring complex) in the folding of cytoskeleton proteins such as actin and 
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Figure 1.3. A schematic of GTR1.3 polyA gene trap. 
A. The insertion of GTR1.3 in Pfdn1. 
The long terminal repeats (LTRs) direct integration of the 
retrovirus vector.  Upstream exons (1-3) of the Pfdn1 gene splice 
to the 3’Puro-LacZ mutator cassette. A neomycin resistance gene 
(Neo) expressed from the RNA polymerase II promoter (PolII) 
splices to exon 4 of Pfdn1. Fusion transcripts expressed by the 
occupied gene are indicated. 
B. Selective cloning of Neo fusion transcripts. (From Lin, et al. 
manuscript submitted)  
A NotI restriction site and intron were engineered in the 
neomycin resistance gene (Neo), enabling selective cloning of 
Neo fusion transcripts. Only 3’RACE products amplified from 
spliced fusion transcripts can generate a functional Neo resistance 
gene which confers Kanamycin resistance in E. coli. This design 
favors cloning of long and specific 3’ RACE products and 
accelerates identification of trapped genes. 
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tubulin (Hansen, Cowan et al. 1999; Siegert, Leroux et al. 2000; Martin-Benito, 
Boskovic et al. 2002). Yeast lacking prefoldin function are viable, yet develop  
severe cytoskeletal defects, which are similar to the phenotype of temperature-
sensitive TRiC mutants (Vainberg, Lewis et al. 1998).  
An Embryonic Stem (ES) clone containing a mutation in Pfdn1 was 
identified from a gene entrapment library of 129sv ES cells (Lin et al. Manuscript 
submitted). GTR1.3 consists of a splicing acceptor (SA), 3’ fragment of 
puromycin resistance gene (Puro3’) followed by internal ribosome entry site 
(IRES) and lacZ reporter, PolII promoter, an intron-split Neomycin resistance 
gene (Neo) and a splicing donor (SD) (Fig. 1.3A). Trapped exons and polyAs 
were recovered in 3’ RACE products, via an efficient selective cloning strategy 
on a split Neo gene (Fig. 1.3B). The location of retroviral insertion was identified 
by inverse polymerase chain reaction PCR. Pfdn1 mutant clones were injected 
into blastocysts and gave rise to germline chimeras.  
GTR1.3 was inserted upstream of Pfdn1 Exon4, which encodes a 
significant part of the coiled-coil domain. The function of this domain, which is 
essential to the interaction between prefoldin and its substrates, is very likely to be 
disrupted by the insertion of GTR1.3. In addition, the cytoskeleton defects in 
prefoldin-deficient yeast suggest the non-redundant function of Pfdn1 in 
cytoskeleton maintenance. As such, I set my goal to study the in vivo functions of 
mammalian Pfdn1 and the impact of loss of prefoldin function in Pfdn1-deficient 
cells. 
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My study revealed that the insertion of the polyA trap GTR1.3 ablated 
expression of Prefoldin 1. Loss of prefoldin function impaired cytoskeletal 
organization, as indicated in Pfdn1-deficient embryonic fibroblasts (MEFs) and B 
lymphocytes. Null mutant mice were marked by premature death, dwarfism, 
defective development in the central nervous systems (CNS), defective 
hematopoiesis and lymphopoiesis. Deficiencies of the Pfdn1 null mice indicate 
that Pfdn1 encodes non-redundant functions required for mouse development and 
survival, presumably by affecting cytoskeleton formation (Cao et al., 2005 
manuscript in preparation). Gene entrapment of Pfdn1 and the deficiencies of 
Pfdn1 null mice will be described further in Chapter III. 
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CHAPTER II 
 
SSRP1/T160: AN HMG-BOX PROTEIN REQUIRED FOR CELL 
VIABILITY 
 
Introduction 
Chromosomal DNA is packaged in a nucleic acid-protein structure known 
as chromatin. The highly ordered structure of chromatin protects genomic DNA 
from physical stress and provides a platform for a wide variety of transactions 
involving DNA. In addition to histones, the basic structural component of 
chromatin, additional chromatin-associated proteins such as the High Mobility 
Group (HMG) proteins manipulate DNA structure and facilitate the assembly of 
nucleoprotein complexes (Bustin and Reeves 1996). This chapter will describe 
my studies on one of the HMG-box proteins, Structural Specific Recognition 
Protein 1 (SSRP1). This introduction will provide the historical background on 
Ssrp1 and provide the rationale for targeting Ssrp gene in mice. 
 
V(D)J recombination and the discovery of  mouse SSRP1/T160. 
Mouse SSRP1/T160 was initially discovered as a potential regulator of 
lymphocyte-specific recombination. To fight against numerous pathogens, 
mammals develop a huge repertoire of lymphocytes that express antibodies with 
different antigen specificities. The diversity of the antibodies and receptors, made 
from a far smaller pool of genes, is provided by somatic gene rearrangements of 
V (variable), J (joining), and/or D (diversity) genes. This so called V(D)J 
recombination is mediated by recombinases encoded by recombination activating 
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genes 1 and 2 (RAG-1, RAG-2).  These lymphocyte-specific recombinases 
recognize DNA recognition signal sequences (RSS) located in the intervening 
DNA 3' of each V segment, 5' of each J segment and flanking both sides of each 
D segment. Additional accessory proteins that are widely expressed in many cell 
types are also involved in the breakage and re-ligation of immunoglobulin gene 
segments (Gellert 2002). 
In the search for DNA binding components that might be involved in 
V(D)J recombination, Sakano's group screened a cDNA expression library from a 
mouse pre-B cell line with a probe containing a concatemer of the 12-bp RSS. 
Clone λT160 was isolated from this screen, and the corresponding gene encodes a 
protein of 80.6 kD. This protein bound to DNA probes containing RSS in 
southwestern assays, but not to a DNA probe containing a mutated RSS. (After 
the discovery of human SSRP1, T160 was identified as a mouse ortholog, hence 
mouse SSRP1/T160.) Homology searches revealed that SSRP1/T160 possesses a 
DNA-binding motif that has 56% sequence homology to the high mobility group 
domain (HMG box) of HMG1 (Shirakata, Huppi et al. 1991) (Figure 2.1.).  
HMG box proteins play various roles from general chromatin maintenance 
(HMG-1, HMG-2) to transcription regulation (SRY, LEF-1) (Bianchi and 
Beltrame 2000). Despite reports indicating various new functions, members of 
this family share a common feature of manipulating DNA structure and 
facilitating the assembly of nucleoprotein complexes. Deletion of the HMG box 
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Figure 2.1 HMG box and major domains in Mouse and Human SSRP1. 
Mouse SSRP1/T160 and human SSRP1 share 98% sequence identity, 
highlighted by the acidic, basic and HMG box motifs that are all highly 
homologous. HMG box (amino acid 539~614) of mouse SSRP1/T160 has 56% 
sequence homology to HMG box (Amino acid 85~160) of HMG-1. 
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destroys the DNA binding activity of mouse SSRP1 (Shirakata, Huppi et al. 
1991). The mouse Ssrp1 gene is located near the Rag-1 and Rag-2 genes on 
mouse chromosome 2 (as their human homologs on Chromosome 11) (Huppi, 
Siwarski et al. 1993). This genetic evidence suggests a linkage between SSRP1 
and RAG-1, RAG-2, and therefore its possible participation in V(D)J 
recombination.  
The regulation of V(D)J recombination is interrelated to that of p53-
mediated DNA damage response (Guidos, Williams et al. 1996). Accumulation of 
"Broken" V(D)J coding ends in  DNA-dependent protein kinase (DNA-PK)  
deficient SCID lymphocyte precursors activates a p53-dependent DNA damage 
checkpoint. This suggests a DNA repair-related mechanism that distinguishes 
well-coordinated recombination from DNA damages in normal cells. Potential 
connections among V(D)J recombination, DNA damage response and 
SSRP1/T160, were especially interesting in light of the potential involvement of 
human SSRP1 in cellular response to DNA damage caused by anti-tumor agents 
described in the next section (Bruhn, Pil et al. 1992). 
 
Human SSRP1 and cisplatin. 
Human SSRP1 was discovered by screening a human B-cell cDNA 
expression library for proteins that bind DNA modified by cisplatin (cis-
diamminedichloroplatinum (II)), a potent anti-tumor agent (Toney, Donahue et al. 
1989; Bruhn, Pil et al. 1992). The protein expressed in one positive clone was 
tested for binding specificity in southwestern assays and bound strongly to DNA 
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probes modified by cisplatin, but did not bind to unmodified DNA or DNA 
modified with the clinically ineffective compound, trans-DDP (trans-
diamminedichloroplatinum (II)). The full-length cDNA encoded an HMG box 
protein with 98% sequence identity to mouse T160. Since the protein bound 
cisplatin-modified DNA rather than a specific DNA sequence, it was named the 
Structure Specific Recognition Protein (SSRP1) (Bruhn, Pil et al. 1992). The 
specific recognition of cisplatin-modified DNA by SSRP1 suggests its 
involvement in cellular responses to cisplatin DNA damage.  
Cisplatin has been a highly effective antitumor drug on a variety of 
cancers, including testicular, ovarian, head and neck cancer (Cohen and Lippard 
2001). Although cisplatin reacts with various cellular components, the critical 
target for cisplatin is generally accepted to be DNA, as indicated by high 
sensitivity to cisplatin of cells with defects in DNA repair. The relatively low 
concentration of Cl ions in the cell facilitates hydrolysis of the chloride ligands of 
the drug. The hydrolyzed forms, once in the nucleus, generate mainly intrastrand 
d(GpG) and d(ApG) DNA crosslinks (Takahara, Rosenzweig et al. 1995). Such 
adducts bend the DNA duplex toward the major groove and unwind the DNA 
helix. This provides a distorted structure that probably mimics DNA structures to 
which HMG box proteins (SSRP1, HMG1, HMG2, Ixr1 etc.) normally bind 
(Brown, Kellett et al. 1993; Ohndorf, Whitehead et al. 1997). 
The DNA damage caused by cisplatin, if not repaired, will cause defects in 
DNA replication and transcription, especially in rapidly growing tumor cells. Two 
models have been proposed to explain the role of HMG box proteins in the repair 
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of cisplatin induced DNA damage. In the "damage recognition" model, HMG box 
proteins may bind to cisplatin DNA adducts and act as a damage-recognition 
element, recruiting the repair complex to the site of damage. The “repair 
shielding” model proposes that the binding of HMG box proteins to the adduct 
blocks the repair complex, causing cell death in rapidly growing cells. Support for 
the "repair shielding model" is suggested by a report that a yeast strain containing 
an inactivated Ixr1 gene (a yeast homologue of mammalian Ssrp1) was half as 
sensitive to cisplatin as the parental strain (Brown, Kellett et al. 1993). Ssrp1 
deficient cell lines would facilitate studies to distinguish between these and other 
models in mammalian cells. 
Cisplatin kills cancer cells, mainly, by triggering G2 cell-cycle arrest and 
apoptosis. The role of p53 tumor suppressor in this process is well established 
(Lowe, Ruley et al. 1993). p53 is a potent activator of apoptosis, (Stewart and 
Pietenpol 2001) and p53-deficient cancer cells are less sensitive to cisplatin 
(Gallagher, Cairney et al. 1997), while p53 - independent cell sensitivity to 
cisplatin is also documented (Zamble, Jacks et al. 1998). Another pathway 
depending on p73, the product of a p53-related gene, was also discovered in 
cisplatin-induced apoptosis (Gong, Costanzo et al. 1999). Unrepaired cisplatin 
DNA damage induces p73-mediated apoptosis, via activation of c-Abl tyrosine 
kinase, a mediator of cell-cycle arrest (Kharbanda, Ren et al. 1995; Gong, 
Costanzo et al. 1999). Put together, these findings indicated that cisplatin could 
induce two separate pathways dependent on p53 or p73. 
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As reported in 2001, the binding of HMG-1 to cisplatin DNA adducts is 
enhanced by interaction with p53 through its HMG box motif (Imamura, Izumi et 
al. 2001). SSRP1, in a complex with hSpt16, has also been reported to influence 
casein kinase 2-dependent phosphorlyation and the activity of p53 in UV 
irradiated cells (Keller, Zeng et al. 2001). This implies that HMG box proteins 
participate in cisplatin-induced apoptosis, possibly by recruiting specific protein 
to sites of adducted DNA. 
Although cisplatin therapy has been relatively successful on cancers such 
as testicular and ovarian cancers, the drawbacks of this therapy, such as toxic side 
effects, drug resistance and limited efficacy in other cancers, have not yet been 
overcome. A better understanding of the underlying molecular mechanism may 
allow for the rational design of new anti-tumor therapies. Ssrp1 deficient mice 
and/or cells will be useful reagents for studying the role of HMG box proteins in 
the mechanism of cellular response toward cisplatin damage. 
 
SSRP1 is a component of chromatin remodeling complex FACT. 
SSRP1 is also implicated in transcription elongation, as a component of 
FACT (facilitates chromatin transcription) complex (Orphanides, Wu et al. 1999). 
The mammalian FACT was initially characterized as an activity that prevented 
nucleosomes from inhibiting transcriptional elongation in vitro. Transcription of 
class II genes in vitro can be reconstituted on naked DNA with RNA Polymerase 
II and general transcription factors (GTFs) IIB, IID, IIE, IIF and IIH. However, 
chromatin templates, although competent for transcription activation, were 
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defective for transcriptional elongation, due to the inhibitory effect of chromatin 
(for review, (Orphanides, Lagrange et al. 1996). Orphanides et al. screened Hela 
cell fractions for activities that would alleviate the inhibitory effect of chromatin 
on transcriptional elongation, using a reconstituted transcription system consisting 
of minimal transcription apparatus and a chromatin template assembled in 
Drosophila cell extracts (Orphanides, LeRoy et al. 1998).  The transcription 
elongation factor was purified and named FACT (facilitates chromatin 
transcription).  FACT was subsequently revealed to consist of two proteins of 140 
and 80 kD. The smaller component is SSRP1/T160 and the larger component is 
an orthologue of the S.cerevisiae Spt16/Cdc68, an essential yeast protein 
implicated in transcription and cell-cycle regulation (Orphanides, LeRoy et al. 
1998).  
 
The role of FACT and SSRP1 in different organisms. 
FACT complexes are abundant (~1,000,000 copies per nucleus) and highly 
conserved. Counterparts are designated CP in S. cerevisiae, DUF in Xenopus and 
FACT in Drosophila, mouse and human. Both components of the yeast CP 
complex, SPT16/CDC68 and POB3, are required for cell viability. Although 
similar to SSRP1, POB3 lacks an HMG box and relies on an HMG box protein, 
Nhp6a or Nhp6b, to recruit the yeast CP to chromatin (Brewster, Johnston et al. 
2001; Formosa, Eriksson et al. 2001). Thus the functional orthologs of SSRP1 in 
yeast are encoded by two genes, POB3, which lacks HMG box, and the  
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Figure 2.2. Mouse SSRP1/T160 is expressed ubiquitously. (From Hertel, 
De Andrea et al. 1999) 
A. Ssrp1  expression in various mouse organs and tissues assessed by 
Northern blot analysis.  
B. SSRP1/T160 western blot analysis of samples from mouse organs 
and tissues. 
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genetically redundant Nhp6a/6b proteins that consist of little more than an HMG 
box. The Xenopus complex was purified as a duplex DNA-unwinding factor 
(DUF) that simulates DNA replication in ooctye extracts (Okuhara, Ohta et al. 
1999). Drosophila FACT complexes are localized to transcriptionally active 
chromatin on polytene chromosomes (Kelley, Stokes et al. 1999).  
Not necessarily independent of the FACT complex, SSRP1 is widely 
expressed in many tissues, such as thymus, spleen, lymph Nodes, bone marrow, 
testis and ovary and has been implicated in a variety of activities (Hertel, De 
Andrea et al. 1999) (Figure 2.2.). Confocal immuno-fluorescene analysis revealed 
co-alignment between SSRP1 speckles and DNA replication centers visualized by 
incorporated BrdU at mid or late S phase of the cell cycle, suggesting the 
involvement of SSRP1 in DNA replication (Hertel, De Andrea et al. 1999). 
SSRP1 has also been implicated in transcription control, for example, as a 
sequence-specific transcription factor of the embryonic ε globin gene (Dyer, 
Hayes et al. 1998).  Other reports suggested SSRP1 as a coactivator working in 
concert with serum response factor (Spencer, Baron et al. 1999) and the p53-
related p63 protein (Zeng, Dai et al. 2002). 
In summary, SSRP1, most probably as a component of FACT, has been 
implicated in DNA recombination (Shirakata, Huppi et al. 1991), replication 
(Wittmeyer and Formosa 1997; Okuhara, Ohta et al. 1999; Wittmeyer, Joss et al. 
1999), basal and regulated transcription (Brewster, Johnston et al. 1998; Evans, 
Brewster et al. 1998; Orphanides, Wu et al. 1999; John, Howe et al. 2000; Wada, 
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Orphanides et al. 2000), and DNA repair (Keller, Zeng et al. 2001; Yarnell, Oh et 
al. 2001; Keller and Lu 2002). 
 
Embryonic lethality of Ssrp1 deficient mice. 
Shortly after the initial discovery of mouse SSRP1/T160, Dr. Eugene Oltz 
and colleagues targeted the gene via homologous recombination in mouse ES 
cells, in an attempt to obtain Ssrp1 deficient mice for studies on the in vivo 
functions of Ssrp1 gene, especially its role in V(D)J recombination and DNA 
damage response.  
The targeting vector consisted of a Neomycin resistance gene (NEO) 
expressed from phosphoglycerol kinase (PGK) promoter flanked by sequences 
homologous to the Ssrp1 gene. After homologous recombination, the vector 
replaced 3.9 kb of genomic sequences (located between KpnI and XhoI sites) that 
contain exons 14-17 with the PGK-Neo cassette. The vector also contained a 
PGK-TK gene to select against non-homologous inserts (Fig. 2.3A).  The mutant 
allele (designated Ssrp1t) thus deletes the HMG box domain (Exon14, 15) along 
with 87 amino acids from the C-terminus. Targeted ES cells were identified by 
Southern blot hybridization to a flanking sequence probe (Fig. 2.3B).  
Three Ssrp1+/t ES clones independently injected into C57BL/6 blastocysts 
gave rise to germ line chimeras. Agouti offspring inheriting the targeted allele 
were identified by Southern blot, and the mutation was bred into a 129Xsv 
background for 3 generations and subsequently intercrossed to generate  
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Figure 2.3. Targeted disruption of the Ssrp1 gene. 
A. A schematic diagram of the genomic organization of Ssrp1 gene, the 
targeting vector and the mutated allele after the homologous recombination. 
The locations of sequences used as a probe for Southern blot hybridization 
and PCR primers (1, 2, 3, a, b, and c) are indicated. For positive selection, 
the targeting vector contained a neomycin resistance gene (Neo) expressed 
from the phosphoglycerol kinase (PGK) gene promoter. The Neo gene 
replaced sequences of the Ssrp1 gene located between the Kpn I and Xho I 
sites.  The targeting vector also contained a Herpes Simplex Virus thymydine 
kinase (TK) gene for negative selection.  
B. Southern blot analysis showing correct targeting of the Ssrp1 gene.  
Genomic DNA from ES cell clones isolated following positive/negative 
selection was digested with Bam HI and analyzed by Southern blot 
hybridization using the 3’ flanking probe shown in Fig 2.3A. The 9.5 kb 
band represents the wild type (+) allele, and the 2.3 kb band corresponds to 
the correctly targeted allele (t). 
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homozygous mutant mice. However, no Ssrp1t/t mice were detected among 
offspring of heterozygote intercrosses. 
 
 Rationale for further study on Ssrp1 mutation. 
 At the onset of my project, it was already clear that SSRP1/T160 is 
required for mouse viability although the timing of embryonic death was not 
known. Moreover, it remained unclear whether SSRP1/T160 would also be 
required for cell viability. If not, null cell lines could be isolated from 
homozygous mutant embryos for biochemical studies on gene functions. Even if 
SSRP1 mice died early in development, it might be possible to establish null ES 
cells from pre-implantation blastocysts. An abundant nuclear protein hnRNP C, 
for example, was required for late embryonic development, but not for cell 
viability (Williamson, Banik-Maiti et al. 2000). The isolation of hnRNP C null ES 
cells revealed the replacement of CARG in hnRNP complex and suggested the 
involvement of hnRNPc in the nuclear retention of unspliced RNA transcripts 
(Williamson, Banik-Maiti et al. 2000)and unpublished results). 
 If Ssrp1 is not required for cell viability, Ssrp1 deficient cells would be 
valuable reagents to study the cellular function of SSRP1/T160, especially in the 
context of V(D)J recombination and DNA damage response, as described earlier. 
The capacity to complete V(D)J recombination could be tested in Ssrp1 deficient 
ES cells to determine whether SSRP1/T160 participated in this recombination. 
Sensitivity to various anti-tumor drugs could be tested in cells expressing 
different levels of SSRP1/T160. Furthermore, the role of SSRP1/T160 in 
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cisplatin-induced apoptosis pathways would be determined, in the context of p53 
or p73 pathway. In addition, successful rescues from embryonic lethality were 
reported by crossing mutations in genes involved in cellular responses to DNA 
damage, including BRCA1, Lig4, and XRCC4 into a p53-null background 
(Ludwig, Chapman et al. 1997; Frank, Sharpless et al. 2000; Gao, Ferguson et al. 
2000). Similarly, crossing the Ssrp1 mutation into the p53-null background may 
alleviate the lethal phenotype. If the lethality in Ssrp1 deficient mice or cells was 
not relieved by the additional loss of p53, then Ssrp1 is likely to function 
differently than other DNA repair proteins and independently of p53. 
Consequently, the effects of Ssrp1 mutation in mice and cells were further studied 
as described in the rest of this chapter.  
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Results 
 
 
Ssrp1 expression is reduced in ES cells with the targeted mutation. 
ES cells with the targeted Ssrp1 mutation were obtained from the 
laboratory of Dr. Eugene Oltz (Vanderbilt University). Four Ssrp1+/t ES clones 
independently injected into C57BL/6 blastocysts gave rise to germ line chimeras.  
Agouti offspring inheriting the targeted allele were identified by either Southern 
blot or PCR analysis, and the mutation was bred into a 129sv or C57BL/6 
background for 3 generations before being intercrossed. 
Since SSRP1 is expressed in many cell types, including ES cells, the 
effects of the targeted mutation on SSRP1 expression could be assessed by 
western blot analysis.  As shown in Figure 2.4, clones containing the targeted 
allele expressed approximately half as much SSRP1 as wild-type cells.  
Moreover, truncated proteins potentially encoded by the targeted allele were not 
detected.    
 
Ssrp1 is required for early embryonic development. 
Ssrp1+/t mice were intercrossed in attempt to generate homozygous mutant 
mice. However, no Ssrp1t/t mice were detected among 220 offspring analyzed 
(Fig. 2.4 and Table 2.1). To determine the stage at which the homozygous mutant 
mice die, embryos from timed matings were genotyped after different times of 
gestation (Table 2.1).  Again, none of the embryos that could be dissected from 
decidua at embryonic day (E) 6.5 to 8.5 was homozygous for the targeted allele.  
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  Figure 2.4. Targeting of Ssrp1 assessed in ES cells and mice.  
A. Western blot analysis of SSRP1 expression in wild type and 
heterozygous, targeted ES cells. Whole cell extracts from Ssrp1+/+
and Ssrp1+/t ES cells were analyzed with antisera against the amino 
terminal region of SSRP1.  The native, 86 KDa SSRP1 protein was 
detected (arrow) in both cell types, while no truncated proteins were 
detected in Ssrp 1+/t cells. The mobility of the 97 and 66 KDa 
molecular weight standards is shown. 
B. PCR genotyping of wild-type and heterozygous mutant mice. 
Primers a, b and c (Fig 1A) were mixed and used to amplify 
sequences corresponding to the wild-type (374 nt) and targeted (250 
nt) alleles.  Tail DNA from 3 week-old offspring produced by 
crossing Ssrp1+/t heterozygotes (lanes 1-7) and a sample lacking 
DNA (lane 8) were amplified by PCR and fractionated on a 1.5% 
agarose gel, together with molecular weight markers (lane 19).  3 of 
the animals analyzed here were wild-type, 4 were heterozygous, 
while none was homozygous for the targeted allele. 
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However, embryos in 16 out of 60 decidua examined were nearly or completely 
resorbed and could not be genotyped.  Moreover, their proportion (26.7%) was 
sufficient to account for the absence of homozygous mutants.  Embryos were also 
examined at E5.5 in serial sections cut through intact decidua.  Once again, the 
presumptive homozygous mutant embryos (4 out of 16) were almost completely 
resorbed (Fig. 2.5).  
 
Table 2.1. Genotypes of offspring and embryos produced by Ssrp1+/t 
intercrosses.  Mice heterozygous for the targeted mutation in the Ssrp1 gene were 
mated and embryos and progeny of the indicated ages were genotyped.   
*This total does not include 16 empty deciduas that could not be genotyped. 
 
 
Age +/+ +/t t/t Total 
 
3 weeks 
 
 
75 
 
145 
 
0 
 
220 
E7.5-8.5 
 
13 31 0 44* 
E3.5 
 
32 54 29 115 
 
 
The observed decidual reactions suggested that the mutant embryos die 
after implantation.  To test this idea further, 105 pre-implantation, blastocyst-
stage embryos (E3.5) were genotyped (Fig. 2.6) by using a nested PCR strategy 
(Fig. 2.3A).  29 homozygous mutant blastocysts were detected, together with 32 
wild type and 54 heterozygous embryos—consistent with a Mendelian 
distribution (Table 2.1).  The mutant blastocysts appeared morphologically 
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normal (Fig. 2.6). Taken together, these results suggest that Ssrp1t/t embryos die 
between implantation (E4.0) and E5.5. 
 
 
 
 
 
 
Figure 2.5. Histological sections of E5.5 embryos.  
Decidua containing E5.5 embryos from Ssrp1+/t intercrosses 
were sectioned and stained with hematoxylin and eosin. 
Representative normal (A) and presumptive homozygous 
mutant (B) embryos are shown. The panels are reproduced at 
the same magnification (bar, 100 μm) 
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Figure 2.6. PCR genotyping of E3.5 blastocysts.  
(A) Blastocysts from Ssrp1 heterozygous intercrosses were analyzed by nested 
PCR, using primers 1, 2, 3 and a, b, c (Fig 2.3.A) in the first and second rounds of 
amplification, respectively. (B) Phase contrast photomicrographs of E3.5 
blastocysts of the indicated genotypes are shown.  Ssrp1t/t blastocysts appear 
morphologically normal. 
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 Defective outgrowth of ICM cells from Ssrp1t/t blastocysts 
Embryonic stem (ES) cell lines are readily derived from the inner cell 
mass (ICM) of E3.5 blastocysts, if the cells are maintained under conditions that 
suppress their differentiation.  Cell lines homozygous for early embryonic lethal 
mutations can also be derived, when the affected genes are not required for the 
growth or viability of ICM cells.  For example, ES cells deficient in hnRNP C and 
protein arginine methyltransferase 1 were successfully isolated in our laboratory, 
even though the mutant embryos died at or before E6.5 (Pawlak, Scherer et al. 
2000; Williamson, Banik-Maiti et al. 2000).  Ssrp1-deficient ES cells could 
provide a valuable system in which to study the biochemical functions of SSRP1.  
However, when blastocysts from Ssrp1+/t intercrosses were cultured in vitro, none 
of the 12 resulting ES cell lines was homozygous for the targeted allele (data not 
shown).  By contrast, eight lines were heterozygous for the mutant allele and four 
were wild-type.  The numbers, while relatively small, are consistent with a 
Mendelian distribution, assuming homozygous mutant cells are selectively lost 
during cultivation.  For reference, the probability (Chi square) of not recovering a 
homozygous mutant from among 12 progeny due to chance alone is 0.08.  
The failure to recover homozygous mutant ES cell lines raised questions 
about whether SSRP1 is required for the growth or viability of ICM cells.  To 
address this issue, 32 blastocysts from Ssrp1+/t intercrosses were individually 
cultured on mouse embryonic fibroblast (MEF) feeder cells and examined daily.  
During the first 24 hours, all of the embryos attached and hatched from the zona  
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Figure 2.7. Defective outgrowth of Ssrp1 homologous mutant blastocysts. 
E3.5 blastocysts from Ssrp1 heterozygous intercrosses were cultured in vitro for 4 
days, both with (A, B) and without (C, D) mouse embryo fibroblast feeder layers.  
All embryos attached within 24 hours and hatched from their zona pellucidae.  
The inner cell mass (ICM) of Ssrp1+/t embryos produced adherent colonies of 
proliferating cells (A, C); whereas, ICM cells from Ssrp1t/t embryos died and/or 
detached from the culture vessel. 
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pellucidae.  After 4 days of culture, the ICMs from 23 blastocysts formed well-
delineated colonies on top of the more adherent trophoblast giant (TG) cells (Fig. 
2.7A). ICM cells from the remaining 9 blastocysts, after limited proliferation, 
appeared to degenerate and/or detach from the dish (Fig. 2.7B).  Cells from the 23 
ICM-derived colonies were collected into drawn glass capillaries and were 
analyzed by PCR to determine their genotypes.  As summarized in Table 2, eight 
of the colonies were wild type, 15 were heterozygous for the targeted allele, and 
none was homozygous for the mutation.   
31 additional blastocysts were cultured without MEFs to eliminate the 
potential for contamination by wild-type feeder cells that might interfere with 
genotyping.  After 3 to 4 days of culture, the ICM from 25 blastocysts formed 
colonies, although these were smaller than those produced on MEF feeder cells 
(Fig. 2.7C). ICM cells from the remaining 6 blastocysts degenerated and/or 
detached from culture vessel, instead of forming distinct colonies (Fig. 2.7D).  
Two of the defective outgrowths could not be genotyped, but the other four were 
Ssrp1t/t.  The genotypes of the 25 normal blastocyst-derived colonies included 7 
wild-type, 18 heterozygotes, and no homozygous mutants (Table 2.2).  Taken 
together, these results indicate that the murine Ssrp1 gene is necessary for the 
growth and/or survival of the ICM. 
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 Table 2.2. Genotypes of blastocysts-derived colonies cultured with or without 
mouse embryo fibroblast feeder layers (MEFs).  E3.5 day embryos produced 
by mating mice heterozygous for for the targeted mutation in the Ssrp1 gene were 
cultured with and without MEF feeder layers and were genotyped by nested PCR 
after 4 days.  *These colonies had degenerated and could not be genotyped. 
 
 
Type 
 
 
+/+ 
 
+/t 
 
t/t 
 
Unknown 
 
Total 
With MEFs 
    
Normal ICM 
colonies 
8 15 0 0 23 
    Aberrant ICM 
colonies 
0 0 0 9* 0 
Without MEFs     
Normal ICM 
colonies 
13 26 0 0 9 
Aberrant ICM 
colonies 
0 
 
0 8 3 1 
 
 
 
Increased numbers of apoptotic cells in Ssrp1-deficient blastocysts 
SSRP1 protein has been reported to bind V(D)J recombination sequences 
and cisplatin adducts, suggesting a possible role in DNA repair and/or 
recombination (Malone, Clark et al. 1991; Shirakata, Huppi et al. 1991).  DNA 
repair defects associated with the Ssrp1 mutation could result in cell death by 
apoptosis and contribute to the rapidity with which Ssrp1-deficient cells lose 
viability both in vivo and in vitro.  While Ssrp1-deficient blastocysts appear 
normal, freshly isolated E3.5 embryos were analyzed for the presence of apoptotic 
cells by terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling 
(TUNEL). 
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Figure 2.8.  TUNEL staining of wild type and Ssrp1-deficient 
blastocysts.  
E3.5 blastocysts from Ssrp1+/t intercrosses were fixed, permeablized, and 
then stained with TUNEL mix (A to C) and with DAPI (D to F). The 
blastocysts were genotyped as Ssrp1+/+ (A and D) and Ssrp1t/t (B and E).  
A DNase I treated Ssrp1+/+ blastocysts (C and F) provided a positive 
control for DNA fragmentation. 
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  73 blastocysts, of which 24 were wild-type and 20 were homozygous for 
the Ssrp1 mutation, were stained, photographed, genotyped and the apoptotic cells 
were counted blind from coded photographs.  Wild-type, heterozygous and 
mutant embryos averaged 1.2 ± 1.2, 1.7 ± 1.7, and 2.6 ± 3.4 TUNEL-positive 
cells per blastocyst, respectively, as illustrated in Figure 2.8.  The difference 
between wild-type and mutant embryos, although relatively small, was 
statistically significant (p < 0.04), while the difference between heterozygous and 
wild-type embryos was not significant (p < 0.09).  However, these differences do 
not appear to account for the growth and/or survival defects associated with the 
Ssrp1 mutation.   
 
p53-deficiency does not rescue embryonic lethality caused by the Ssrp1t 
mutation. 
 
As an important regulator of the cellular responses to DNA damage, the 
p53 tumor suppressor could interact with SSRP1 on several levels.  First, a 
protein complex containing SSRP1 and SPT16 (FACT) has been reported to 
influence CK2-dependent phosphorylation and activity of p53 (Keller, Zeng et al. 
2001).  Since FACT enhances transcription elongation on chromatin templates in 
vitro, the complex has been postulated to activate p53 as part of a transcription-
dependent mechanism for recognizing DNA damage.  Second, several genes 
involved in the cellular response to DNA damage, including BRCA1, Lig4 and 
XRCC4, are required for embryonic development.  Death of BRCA1, Lig4 and 
XRCC4 mutant embryos occurs at or before E7.5, E17.5, and E16.5, respectively, 
and requires active participation by the p53 tumor suppressor, which promotes 
 44
apoptosis in DNA repair-deficient cells (Ludwig, Chapman et al. 1997; Frank, 
Sharpless et al. 2000; Gao, Ferguson et al. 2000). As a consequence, inactivating 
mutations in p53 delay or prevent embryonic lethal phenotypes associated with 
these DNA repair deficiencies. 
  To assess the role of p53 in the death of Ssrp1-deficent embryos, mice 
with mutations in Ssrp1 and p53 were intercrossed.  Since the Ssrp1 and p53 
genes are unlinked, one in 16 offspring from mice doubly heterozygous for 
inactivating Ssrp1 and p53 mutations is expected to be homozygous for both 
mutations if p53 deficiency rescues Ssrp1t/t embryos from embryonic death.  
However, none of the 106 pups analyzed, including 21 p53-/- offspring, was 
homozygous for the Ssrp1 mutation.  65 E7.5 to E12.5 embryos were also 
genotyped, but none was homozygous for the targeted allele. Finally, p53 status 
had no discernable effect on the outgrowth of Ssrp1t/t blastocysts.  Thus, of 25 
blastocysts produced by intercrossing Ssrp+/t heterozygotes in a p53-null 
background, 8 Ssrp+/+ and 12 Ssrp+/t gave rise to normal ICM-derived colonies.  
The remaining 5 blastocyts produced defective colonies, including 3 that were 
Ssrpt/t and 2 that could not be genotyped.  These results indicate that p53 does not 
contribute to the growth and/or survival defects of Ssrp1 mutant embryos, either 
in vivo or ex vivo. 
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Discussion 
 
Mouse Ssrp1 is an essential gene. 
 My results showed that murine Ssrp1 is essential for the growth and 
survival of early embryonic cells both in vivo and ex vivo.  Thus, while a number 
of high mobility group (HMG) chromatin-associated proteins are encoded by the 
mouse genome (Baxevanis, Bryant et al. 1995), none of these HMG-box family 
members appears able to compensate for the loss of Ssrp1 function.  Ssrp1 is 
required for the survival of post-implantation blastocysts and for the viability of 
cells of the ICM—phenotypes associated with genes essential for cell viability 
(Carlone and Skalnik 2001; Herceg, Hulla et al. 2001; Medghalchi, Frischmeyer 
et al. 2001). The results are consistent with studies linking Ssrp1 expression with 
cell proliferation (Hertel, De Andrea et al. 1999) and with anti-sense ablation 
experiments implicating Ssrp1 in the proliferation of murine fibroblasts (Hertel, 
Foresta et al. 1997).  However, it is still possible that the gene is dispensable in 
some cell types, such as the case of Brg1 gene (Bultman, Gebuhr et al. 2000).  
 The targeted mutation deleted 87 amino acids from the carboxyl-terminus 
of SSRP1, including the HMG box.  Since the HMG box is required for DNA 
binding, the mutation is expected to inactivate SSRP1 function.  The mutation 
was inherited as simple, recessive embryonic lethal trait; however, due to the 
severity of the growth and/or survival defects exhibited by Ssrp1-deficient 
embryos, I was unable to recover sufficient numbers of homozygous mutant cells 
to determine if the targeted mutation is a null allele.  ES cells heterozygous for the 
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mutation expressed approximately half as much SSRP1 protein as wild-type cells, 
and did not appear to express truncated forms of the protein.  Moreover, 
heterozygous mice displayed no phenotypes that might result from the trans-
dominant activity of a truncated protein. 
 
SSRP1 and HMG protein family 
While SSRP1 shares features in common with other HMG box proteins, 
the protein also has several unique features that distinguish it from other HMG 
family members.   SSRP1 is most similar to HMG-1 within the HMG domain, but 
unlike HMG-1, SSRP1 is capable of binding DNA in a sequence specific manner 
(Dyer, Hayes et al. 1998).  SSRP1 also contains only a single HMG domain, like 
the sequence-specific HMG box proteins, SRY and LEF-1/TCF-1a.  Because of 
these and other features, SSRP1 was classified into a distinct subfamily of HMG 
domain proteins (Baxevanis, Bryant et al. 1995).  Since targeted mutations in 
other HMG family members have thus far resulted in far more restricted 
phenotypes (Verbeek, Izon et al. 1995; Calogero, Grassi et al. 1999; Bianchi and 
Beltrame 2000; Staal and Clevers 2000; Britsch, Goerich et al. 2001; Kanai-
Azuma, Kanai et al. 2002; Vasseur, Hoffmeister et al. 2002), the present study 
provides further evidence that Ssrp1 encodes unique, non-redundant functions.   
 
Functions of SSRP1 implicated in this study 
As a component of the phylogenetically conserved FACT/DUF/SPT16-
POB3 complex, SSRP1 appears to assist in chromatin remodeling during 
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transcription initiation/elongation and DNA replication (Wittmeyer and Formosa 
1997; Okuhara, Ohta et al. 1999; Orphanides, Wu et al. 1999; Wittmeyer, Joss et 
al. 1999; John, Howe et al. 2000; Wada, Orphanides et al. 2000). In S. cerevisiae, 
orthologous functions of SSRP1 appear to be supplied by POB3, which is similar 
to SSRP1 but lacks the HMG-box domain, and by Nhp6a/Nhp6b, genetically-
redundant proteins consisting of little more than HMG boxes (Brewster, Johnston 
et al. 2001; Formosa, Eriksson et al. 2001). The phenotype of the Ssrp1t mutation 
in murine embyros provides additional evidence for phylogenetic conservation 
between SSRP1 and POB3, as POB3 is required for cell viability in S. cerevisiae.   
Although initially discovered as a potential regulator of V(D)J 
recombination, the preferential binding of SSRP1 to the RSS probe but not the 
mutant probe with a single nucleotide mutation, is more likely the consequence of 
its secondary the structure rather than primary nucleotide sequence. Noteworthy, 
HMG-1 and HMG-2, which contain similar HMG box domains, are able to 
stimulate V(D)J cleavage at the site of RSS in in vitro assay (van Gent, Hiom et 
al. 1997). Thus the binding of SSRP1 on RSS appears to be related to the general 
ability of HMG proteins to bind distorted DNA conformations (Gariglio, Ying et 
al. 1997; Vasseur, Hoffmeister et al. 2002). 
Several observations suggest SSRP1 may play a role in DNA repair. 
SSRP1 binds cisplatin DNA adducts (Malone, Clark et al. 1991), and SSRP1 has 
been reported to enhance the activities of the p53 tumor suppressor (Keller, Zeng 
et al. 2001; Keller and Lu 2002), and the p53-related protein, p63 (Zeng, Dai et al. 
2002).  As a component of the FACT complex, SSRP1 would be positioned to 
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activate p53-dependent responses to DNA damage at the sites of transcription or 
DNA replication.  However, phenotypes caused by deficiencies in several DNA 
repair genes (e.g. Brca1, Lig4 and XRCC4) are less severe than those caused by 
loss of Ssrp1, and phenotypes resulting from these DNA repair defects, unlike 
Ssrp1 deficiency, are reduced in severity in the absence of p53 (Ludwig, 
Chapman et al. 1997; Frank, Sharpless et al. 2000; Gao, Ferguson et al. 2000).  
Inactivation of Mdm2, a negative regulator of p53, also results in early embryonic 
lethality, but has no effect in p53 null animals (Montes de Oca Luna, Wagner et 
al. 1995). Thus, the phenotype of the Ssrp1t mutation and apparent lack of genetic 
interaction with p53, suggest that SSRP1 does not function primarily in DNA 
repair or as an upstream activator of p53.   
In summary, while genetic inferences are necessarily indirect, Ssrp1 
appears to encode non-redundant functions that play essential roles in cellular 
metabolism.  
 
Attempts at alternative genetic manipulations 
While direct functional studies are hampered by the lack of Ssrp1-
deficient cells, it should be possible to develop a conditional deficient cell line. A 
conditional complementation vector would be constructed that contains an Ssrp1 
expression cassette and a reporter gene (IRES followed by EGFP or mouse CD24) 
flanked by loxP sites, and a selectable marker (puromycin resistence gene). Ssrp1 
heterozygous ES cells will be transfected with conditional vectors and selected in 
Puro selection media. Surviving cells, supposedly with stable incorporation of the 
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conditional vector, will be cultured in high concentration of G418 for loss-of-
heterozygozity (LOH) (methods described in Donahue et al. manuscript 
submitted). The resulting clones would contain both mutated Ssrp1 alleles, while 
cells live relying on SSRP1 expressed by the inserted conditional vector. This 
conditional null cell line, in the presence of Cre recombinase (cell-permeable Cre 
(Jo, Nashabi et al. 2001; Lin, Jo et al. 2004) directly delivered into the cell or Cre 
expressed by a transfected Cre expression plasmid (Li, Stark et al. 1996)), would 
delete the Ssrp1 expression cassette in Cre/loxP mediated deletion and therefore 
lose de novo expression of SSRP1.  
By design, the conditional Ssrp1 deficient cell line would assist to 
delineate cellular functions of SSRP1 and cellular response to the sudden loss of 
the essential gene Ssrp1. However, whether conditional null cells, after Cre 
manipulation, would be viable long enough for the enrichment of null cells and 
subsequent functional studies, were potential caveats. Together with technical 
difficulties that hampered the construction of the conditional complementation 
vector, this approach was discontinued.  
RNA interference strategy was also attempted to knockdown SSRP1 
expression in various established human and mouse cell lines. An array of 21nt 
interfering sequences were designed and introduced into cells via plasmid or 
retroviral systems that express small hairpin RNA (shRNA) (Brummelkamp, 
Bernards et al. 2002; Yu, DeRuiter et al. 2002).   Unfortunately, no cell line with 
ideal knockdown effect was obtained, partly due to a dilemma that renders the 
selection of efficient knockdown events intractable. Presumably, cells with 
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significantly reduced SSRP1 would have impaired proliferation and/or viability, 
therefore grow slower than the cells that are less affected by RNA interference 
and would be overwhelmed in culture. 
 
Biochemical analysis of transcription elongation 
I also conducted a number of experiments focused on the role of SSRP1 in 
transcription elongation. I hoped to employ systems in which gene expression is 
specifically activated at the level of transcription elongation. These involved 
activation of the HIV LTR promoter by TAT (Ping and Rana 2001; Fujinaga, 
Irwin et al. 2004) and UV activation of p21 transcription elongation (Espinosa 
and Emerson 2001; Espinosa, Verdun et al. 2003). Chromatin 
Immunoprecipitation (ChIP) assays (Kuo and Allis 1999) were used to determine 
if SSRP1 docks on the transcribed region prior to activating transcription 
elongation, or was recruited to the transcribed region as a cofactor of Polymerase 
II complexes engaged in elongation. This study was slowed by technical 
difficulties of ChIP assay. Moveover, during the course of my studies, several 
biochemical and genetic studies established the primarily function of FACT as a 
transcription elongation factor (Belotserkovskaya, Oh et al. 2003; Kaplan, 
Laprade et al. 2003; Saunders, Werner et al. 2003). Drosphila FACT was 
recruited to and tracked on polytene chromosomes with kinetics similar to RNA 
Polymerase II (Saunders, Werner et al. 2003). These advances undermined the 
potential significance of results that I might obtain. Therefore, these studies were 
discontinued.  
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Materials and Methods  
 
Southern blot analysis 
The Ssrp1 genotype of ES cells and mice was assessed by Southern blot 
hybridization to a [32P]dCTP-labeled, 0.7 kb BglII/BamHI probe derived from 
genomic sequences located downstream of the 3’ homolog region of the targeting 
vector, as described previously (Williamson, Banik-Maiti et al. 2000).  
  
PCR genotyping 
The Ssrp1 genotype of E6.5 - E8.5 embryos was assessed by PCR, using a 
mixture of three primers:  
a (5’CCGGCCCAGTAGGTATTTTC),  
b (5’CAGACTGCCTTGGGAAAAGC)  
and c (5’TCCCTCCAAGGAGCTATGTG).  
Each 50 μl reaction mix contained 10 mM Tris-HCl (pH8.3), 5 mM KCl, 1.5 mM 
MgCl2, 200 μM each deoxyribonucleoside triphosphate, each primer at 2 μM, and 
2.5 U of Amplitaq (Roche).  Reactions involved 30 cycles of denaturation (94°C, 
1 min), primer annealing (59°C, 1min), and primer extension (72°C, 2 min). 
The Ssrp1 genotype of E3.5 blastocysts and blastocysts-derived colonies 
was assessed by nested-PCR.  The first reaction used a mixture of 3 primers:  
1 (5’ AGGCTGGCTGTGACTTAGTG),  
2 (5’ACTTGTGTAGCGCCAAGTG),  
and 3 (5’CATCCGTGAGGGCTTACT),  
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as described above but for 20 cycles of denaturation (94°C, 1min), primer 
annealing (55°C, 1 min), and primer extension (72°C, 2 min).  A second round of 
PCR used primers a, b, and c as described above in a 50 μl reaction. 
 Primers used for p53 PCR genotyping include:  
X7 (5’TATACTCAGAGCCGGCCT) 
X6.5 (5’ACAGCGTGGTGGTACCTTAT).  
Neo19 (5’CTATCAGGACATAGCGTTGG) 
The wild type allele was detected using X7 and X6.5 while the null allele (Lowe, 
Schmitt et al. 1993) detected with X7 and Neo19. Reactions involved 30 cycles of 
denaturation (94°C, 1 min), primer annealing (55°C, 1 min), and primer extension 
(72°C, 2 min) as described above. 
 
Isolation and analysis of Ssrp1 mutant cells 
E3.5 blastocysts were isolated and used to derive ES cell lines as 
described earlier (Williamson, Banik-Maiti et al. 2000).  For studies of blastocyst 
outgrowth, E3.5 embryos were cultured, either with or without irradiated mouse 
embryonic fibroblast feeder layers, in ES cell medium [Dulbeccco modified Eagle 
medium (Mediatech) supplemented with 15% Fetal Bovine Serum (heat-
inactivated at 55°C for 30 min), 0.1 mM 2-mercaptoethanol, 100 mM 
nonessential amino acids, 100U/ml Penicillin-Streptomycin (Gibco BRL)].  
The expression of SSRP1 protein in ES cell clones was assessed by 
Western blot analysis. Cell lysates were fraction by electrophoresis on an 8% 
SDS-polyacrylamide gel and transferred onto a PVDF membrane (NEN life 
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science), and SSRP1 proteins were detected by using rabbit polyclonal antibodies 
raised against the aminoterminus of the protein, as described elsewhere (Hertel, 
De Andrea et al. 1999). 
 
Analysis of mutant embryos 
The morphology of post-implantation embryos was assessed from serial 
sections (7 μm) of paraffin-inbedded deciduas stained with hematoxylin and eosin 
(Pawlak, Scherer et al. 2000). Apoptosis in pre-implantation embryos was 
detected with an in situ cell death detection kit (Roche).  Blastocysts were fixed 
with 4% paraformaldehyde in PBS for 15 minutes and then permeablized for 30 
minutes with 0.3% Triton X-100 and 1.5% bovine serum albumin in PBS. 
Blastocysts treated with 0.5 mg/ml DNase I for 10 minutes provided positive 
controls for DNA fragmentation. Embryos were incubated with the TUNEL 
reaction mix for 1 hour at 37°C, and cell nuclei were stained with DAPI (1 mg/ml 
in PBS) for 10 minutes. The embryos were viewed and photographed using a 
fluorescence microscope and then genotyped by nested PCR. 
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CHAPTER III 
 
FUNCTIONS OF MOLECULAR CHAPERONE PREFOLDIN REVEALED 
IN PFDN1 NULL MICE GENERATED BY GENE ENTRAPMENT  
 
 
Introduction 
An important cellular process is the conversion of nascent translation 
products into properly folded functional proteins. Although the three dimensional 
conformations of polypeptides are determined by their linear sequences,  prompt 
and efficient protein folding in the crowded cellular environment often requires 
assistance of a group of proteins termed “molecular chaperones” (Hartl and 
Hayer-Hartl 2002). The maturation of cytoskeletal proteins such as actin and 
tubulin, involves a chaperone named prefoldin, a complex consisting of 6 subunits 
(Vainberg, Lewis et al. 1998). The mouse Pfdn1 gene, which encodes the first 
subunit of prefoldin, was disrupted by a polyA gene trap vector in ES cells and 
the mutation was subsequently introduced into the mouse germline. This 
introduction will briefly describe background information about prefoldin and 
establish the rationale for studying Pfdn1 function of in vivo.  
 
Protein folding and chaperonin 
 To assist the proper folding of nascent peptides and to avoid protein 
misfolding and aggregation, molecular chaperones cooperate with each other in 
protein folding pathways. In eukaryotic cells, the majority of nascent peptides 
form a complex with Heat shock protein 70 (Hsp70s) (Eggers, Welch et al. 1997; 
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Pfund, Lopez-Hoyo et al. 1998), while others require the function of a chaperonin 
(Yaffe, Farr et al. 1992; Sternlicht, Farr et al. 1993). 
Chaperonins are large, multi-subunit, cyclindrical protein complexes with 
a central cavity for the binding and folding of nascent chain substrates (Kim, 
Willison et al. 1994; Spiess, Meyer et al. 2004). There are two groups of 
chaperonins: Group I, includes the bacterial GroEL and mitochondrial Hsp60 
proteins; and Group II, include the archaeal TF55, and eukaryotic TRiC/CCT/c-
cpn [for T-complex polypeptide1 (Tcp1) ring complex or chaperonin-containing 
Tcp1 or cytosol chaperonin (Frydman, Nimmesgern et al. 1992; Gao, Thomas et 
al. 1992; Kubota, Hynes et al. 1994). In eukaryotic cells, TRiC processes the 
folding of approximately 10% of nascent proteins (Thulasiraman, Yang et al. 
1999). Many TRic substrates are cytoskeletal components: α-and β-actin, α-,β- 
and γ- tubulin, actin-related protein V, cofilin and actin-depolymerizing factor 1 
(Frydman, Nimmesgern et al. 1992; Gao, Thomas et al. 1992; Melki, Vainberg et 
al. 1993; Ursic, Sedbrook et al. 1994; Melki, Batelier et al. 1997).  However non-
cytoskeletal substrates have also been identified such as transducin, cyclin E, Von 
Hippel-Lindau (VHL) tumor tumor suppressor (Farr, Scharl et al. 1997; Won, 
Schumacher et al. 1998; Feldman, Thulasiraman et al. 1999), Cdc20 and several 
proteins containing tryptophanaspartic acid (WD) repeats  (Camasses, Bogdanova 
et al. 2003; Siegers, Bolter et al. 2003).  
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 Figure 3.1 Protein folding pathways in eukaryotic cells. 
(From Hartl, Hayer-Hartl et al. 2002) 
The majority of newly synthesized polypeptides may fold 
properly without further assistance. About 15 to 20% of 
peptides reach their native states through a folding reaction 
assisted by Hsp70 and Hsp40, and a fraction of these must be 
transferred to Hsp90 for folding. About 10% of the chaperone-
assisted polypeptides are co- or posttranslationally passed on to 
the chaperonin TRiC in a reaction mediated by PFD. 
 
NAC: Nascent chain-associated Complex.   
PDF:  Prefoldin complex. 
TRiC: Tcp-1 ring complex. 
N: Native conformations of proteins. 
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 A fraction of TRiC-mediated folding also requires one  cytosolic chaperone 
prefoldin, a heterohexameric protein complex that is conserved in archaea, yeast 
(as GimC) but not bacteria (Geissler, Siegers et al. 1998; Vainberg, Lewis et al. 
1998). 
 
Prefoldin functions in the folding of cytoskeleton proteins 
The prefoldin complex consists of 6 subunits, namely prefoldin 1-6, 
Prefoldin was initially purified for its ability to bind unfolded actin (Vainberg, 
Lewis et al. 1998).  The yeast homologue of prefoldin the GimC complex,  
consists of Gim1 through Gim6 proteins.  Deletion of these genes is not lethal, but 
leads to impaired function of the actin/tubulin cytoskeleton. The phenotype is 
similar to that of a temperature sensitive mutation of TRiC, which is required for 
cell viability (Vainberg, Lewis et al. 1998). In in vitro assays, prefoldin binds 
nascent chains of actin and tubulin, but not non-cytoskeletal substrates, and 
presents them to TRiC (Hansen, Cowan et al. 1999).  (Figure 3.1 provides a 
schematic of the pathway). Yeast GimC delivers newly translated actin and 
tubulin to TRiC, as indicated by reduced rate of actin folding in cells lacking 
GimC function.  (Siegers, Bolter et al. 2003). Structural studies revealed that 
prefoldin subunits form a pocket-like structure and interact with nascent peptides 
at the end of their coiled-coils domains (Siegert, Leroux et al. 2000; Martin-
Benito, Boskovic et al. 2002). The interaction between prefoldin, unfolded actin  
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Fig. 3.2. Structure of the prefoldin heterohexamer complex. 
(From Siegert, Leroux et al. 2000) 
 (A-C) Ribbon representation of the prefoldin hexamer shown 
from the side (A), top (B) and bottom (C). All ribbon diagrams 
were generated using Ribbons. (D-F) The molecular surface of 
the prefoldin hexamer. Red color indicates acidic and blue basic 
surface regions. All surfaces were generated using GRASP. 
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and TRiC was also demonstrated by electron microscopy (Martin-Benito, 
Boskovic et al. 2002). (Figure 3.2) Collectively, these genetic, biochemical, 
kinetic and structural studies establish the cellular function of prefoldin as a co-
chaperone that assists in TRiC-mediated folding of cytoskeleton proteins such as 
actin and tubulin (Figure 3.1).  
Actin and tubulin, as basic components of the cytoskeleton, play 
fundamental roles in various cellular functions, such as, maintaining cell shape, 
providing a scaffold for docking and transport of cellular macromolecules, cell 
motility, cell adhesion and cell division. Actin is also involved in tissue-specific 
functions of the cytoskeleton, such as muscle contraction in smooth and cardiac 
muscle, outgrowth of axons and dendrites in neurons, and formation of neuronal 
and immunological synapses.  However, deletion of the alpha-actins in mouse, 
does not lead to embryonic death. (Small, Rottner et al. 1999; Dustin and Cooper 
2000; Luo 2002).  
 
 An Embryonic Stem (ES) clone containing a mutation in Pfdn1 was 
identified from a gene entrapment library of 129sv ES cells generated using 
polyA entrapment vectors (Lin et al. Manuscript submitted). The sequence of the 
3’ RACE product from the p3b3A6 clone matched the fourth and last exon of 
Pfdn1 (Figure 3.3 B), indicating that the retrovirus was inserted into the last 
intron. By design, Pfdn1 -Vector fusion transcript expressed by the mutated allele 
should not contain Exon4, which encodes 27 amino acids of the 122 amino acids 
prefoldin, part of the coiled-coil domain that is required for interactions between 
 60
prefoldin and peptide substrates (Siegert, Leroux et al. 2000). Mice and/or cells 
containing this mutation would assist in delineating the in vivoi functions of 
mammalian Pfdn1. In addition, since the deletion of yeast prefoldin causes 
cytoskeletal defects, it would be interesting to know if Pfdn1 mutants cause 
similar defects in mammalian cells and how these defects might be manifest in the 
whole animal. 
 
In particular I wished to answer the following questions: 
1)  Does the insertion of GTR1.3 in the last exon of Pfdn1 completely ablate 
Pfdn1 expression or does the insert cause a hypomorphic mutation? 
2)  What is the effect of Pfdn1 mutation on mouse development?  The potential 
importance of a functional cytoskeleton suggests that loss of Prefoldin function 
could cause embryonic death, if not cell lethality. 
3)  What is the phenotype of mutant mice if they are viable?  What organ systems 
are specifically affected? 
4)  If mutant cells are viable, do they have specific cellular defects?  Is the 
cytoskeleton altered?  Is actin maturation affected?   Is the assembly or function 
of the cytoskeleton affected? 
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Results 
 
Disruption of the Pfdn1 gene by gene entrapment 
Pfdn1 was disrupted in embryonic stem (ES) cells by the insertion of the 
GTR1.3 gene trap retrovirus.  Gene entrapment involved expression of a 
neomycin resistance gene from transcripts that splice from the GTR1.3 vector to 
the fourth and last exon of the Pfdn1 gene (Figure 3.3 A). The sequence of the 
3’RACE product derived from Neo fusion transcripts is shown in Figure 3.3 B. 
The mutation is expected to disrupt Pfdn1 expression since the resulting Pfdn1-
Vector fusion transcripts lack Exon 4, deleting 27 amino acids of the 122 amino 
acids prefoldin protein.  The deleted sequences contain part of the coiled-coil 
domain that is thought to be required for interactions between prefoldin and 
peptide substrates (Siegert, Leroux et al. 2000).  The location of the provirus in 
the third intron was determined by cloning genomic DNA sequences adjacent to 
the targeting vector by inverse PCR. The sequences of the inverse PCR product is 
shown in (Figure 3.3 C). PCR primers based on the flanking genomic DNA and 
3’LTR sequences were used to genotype wild type and mutant alleles (Figure 3.3 
A). ES cells containing the Pfdn1 mutation were injected into C57BL/6 
blastocysts and gave rise to germ line chimeras. Agouti offspring containing the 
mutated allele were identified by PCR analysis and intercrossed. The offspring of 
heterozygote intercrosses were PCR genotyped (Figure 3.3 D).  
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Figure 3.3. Disruption of the Pdfn1 gene by the insertion of GTR1.3. 
A. A schematic diagram of the genomic organization of Pdfn1 gene, and the 
insertion of the GTR1.3 gene trap retrovirus.  The inverse PCR and 
genotyping primers corresponding to provirus (Up, Dp) and genomic (Ug, 
Dg) sequences are indicated. 
B. Sequence of the 3’ RACE product amplified from Neo-exon4 fusion 
transcripts. 
C. Sequence of the inverse PCR product amplified with Up and Dp primers. 
D. Three-primer PCR analysis of tail DNA samples from 3-week-old offspring 
of Pfdn1 heterozygous intercrosses. The 365bp band and 215bp band 
represent wild type (Ug and Dg) and mutant alleles (Ug and Dp), 
respectively. 
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Figure 3.4. Pfdn1 is expressed in wild type, heterozygous but not 
homozygous mutant mice. 
A. Western blot analysis of Prefoldin 1 expression in WT, heterozygous and 
homozygous mutant Mouse Embryo Fibroblasts (MEFs).  80μg of whole 
cell extracts from Pfdn1 +/+, +/- and -/-cells were analyzed with antisera 
against the internal region of Prefoldin1 (Left panel).  A 20 kDa protein 
was detected in both Pfdn1 +/+ and +/- cells, but not Pfdn1 -/- cells. The 
blot was stripped and reprobed with an anti-HnRNP C antibody to provide 
a loading control. 
B. Northern blot analysis of Pfdn1 transcripts in different tissues. From left to 
right: Muscle,Thymus, Spleen, Gut, Kidney, Liver, Lung, Heart, Brain. 
The blot was reprobed with a glyceroldehyde phosphate dehydrogenase 
(GAPDH) probe to provide a loading control (bottom) 
C. Northern blot analysis of MEFs. 10μg of RNA from Pfdn1+/+, +/-, -/-
MEFs were separated, transferred and detected with radio-labeled probe 
corresponding to 5’ region of Pfdn1 mRNA. A GAPDH re-blot is shown in 
the right panel. 
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The complete disruption of Pfdn1 expression was suggested by Western 
blot analysis of lysates from homozygous mutant MEFs.  A 20 kDa band was 
detected in wild type and heterozygous MEF’s but not in homozygous mutant 
MEFs (Figure 3.4 A left panel).  Equal loading was confirmed by the levels of 
hRNP C detected in parallel Western Blots.  (Figure 3.4A right panel). 
  
Pfdn1 is ubiquitously expressed in mouse organs and tissues (Figure 3.4 
B). Northern blot analysis of RNA from mutant MEFs, revealed the complete loss 
of the wild type Pfdn1 transcript and the appearance of a larger transcript. (Figure 
3.4 C).  Expressed at lower levels, these transcripts presumably correspond to 
fusion transcripts generated by splicing among upstream Pfdn1 exons and the 3’ 
Puro-LacZ sequence carried by the provirus.  However, Western blot analysis 
failed to detect altered proteins expected to be expressed from these transcripts. 
 
Viability and growth of Pfdn1 mutant mice 
36 of the 161 offspring produced by heterozygote intercrosses were 
homozygous for the Pfdn1 mutation, close to a Mendelian ratio. Pfdn1 -/- mice 
were smaller in size than wild type and heterozygous littermates (Figure. 3.5 A), 
grew more slowly (Figure 3.5 B), and most died before 5 weeks of age (Figure 3.5 
C). Some homozygous mutants were distinguishably smaller at birth. Average 
weights of mutant mice at 2, 3 and 4 weeks were 3.9±0.6g (n=14), 5.3±1.0g 
(n=13) and 4.9±1.0g (n=10) respectively, while the wild type and heterozygous  
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 Figure 3.5. Growth and survival of Pfdn1-/- mice. 
A. Pfdn1+/- and -/- littermates at 4 weeks of age. 
B. Growth of Pfdn1-/- mice is severely retarded. 
C. Survival of offspring from Pfdn1+/- intercrosses. 
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 littermates weighed 8.3±0.8g (n=26), 12.7±1.8g (n=22) and 15.7±1.7g (n=17) 
respectively. The weight of Pfdn1-/- mice declined 0.3-0.7g (0.6±0.2g, n=5) 
during the last week before death, indicating physical wasting. In addition, ~40% 
homozygous mutant mice were observed with uncoordinated movement, 
indicating neuromuscular dysfunction. 
 
Histological Analysis of Pfdn1 mutant mice 
8 mutant mice and 8 control littermates 3 days to 5 weeks old were 
sacrificed and examined histologically. Sections from head, chest, hinder quarter 
and internal organs were stained with Hematoxylin and Eosin. All mutant mice 
had overall dwarfism and abnormalities in the brain and spleen. However, 
muscles, eyes, teeth, liver, kidney, gut, heart and lung of the mutants appeared 
normal. In addition, infected sinuses were seen in 3 mutant mice but not in control 
littermates. 
 
Defective Commissures in Central Nervous System 
  Coronal sections through the brain of mice at 2 weeks and 4 weeks 
revealed disorganized and hypocellular Corpus Callosum (CC) in homozygous 
mutant mice (Figure 3.6 B). Dilated ventricles were also observed in mutant 
brains. However, this may be an effect of strain background and /or differences in 
tissue preparation. H&E stains of Sagittal sections, also revealed disrupted 
cerebellar commissures (cbc) in 4 week old mice (Figure 3.6 D).   
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 Figure 3.6. Defective neural commissures in Pfdn1-/- mice. 
Coronal sections through the cerebrum (A.B.) or sagittal sectons through 
the cerebellum (C.D.) of 2 weeks old, Pfdn1+/- (A.C.) and Pfdn1-/-
(B.D.) mice. Corpus callosum (CC) and cerebellar commissure (cbc) are 
indicated. 
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 This cerebellum defect may be responsible for the uncoordinated movements of 
some mutant mice.  While commissure defects are severe and consistent, general 
neuronal defects were not observed. 
 
Defective hematopoiesis in Pfdn1-/- mice 
There were fewer erythrocytes and white blood cells in the peripheral blood of 
Pfdn1-/- mice. Hemoglobin levels in mutant blood cells appeared to be normal. 
Although the reduction in erythrocyte counts was modest, micronuclei were 
prominent in ~2% of the mutant erythrocytes, as compared to 0.1% of wildtype 
and heterozygous mice (Figure 3.7 B). Micronucleated erythrocytes may result 
from defects in DNA synthesis annucleation and/or removal of micronucleated 
cells by spleen macrophages. Increased segmentation appeared in the nuclei of the 
homozygous mutant neutrophils (Figure 3.7 D). 
 
Lymphopoiesis defects in Pfdn1-/- mice  
The spleen and thymus were significantly smaller in Pfdn1-/- mice; 16.9 ± 
4.4% (n=8) of the size of organs from littermate controls, or 36.7 ± 12.3% (n=8) 
of the size after normalizing against body weight. Total cell numbers retrieved 
from these organs were similarly reduced: 12.4 ± 7.1% (n=8) of control organs. In 
mutant spleens, the germinal centers were not clearly defined and the surrounding 
red pulp was disorganized (Figure 3.8 B).  Thymuses from mutant mice were 
smaller but appeared to have normal histology.   
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      Figure 3.7. Hematopoietic defects in Pfdn1-/- mice.  
Erythrocytes in wild type (A) appear normal whereas erythrocytes from 
Pfdn1 deficient mice (B) frequently contain micronuclei (arrows). 
Normal neutrophil (C) and abnormal nuclear segmentation in 
neutrophil from Pfdn1 deficient animal (D).  
 70
 FACS analysis of spleen and bone marrow revealed  significant decreases 
in the number and proportion of B cells in mutant mice; only 27.1 ± 7.6 % (n=5) 
spleen cells were B220 positive, as compared to 62.3 ± 7.8 % (n=5) for wild type 
or heterozygous littermates. Representative FACS profiles are shown in Figure 
3.8 C. In concert with the dramatic change of architecture of the mutant spleen, 
the decreased percentage of B cells indicates defective B cell development in 
mutant mice. The number of T1 (IgMhi, IgDlo, AA4.1hi) cells was reduced to a 
greater extent than mature B cells (IgMlo, IgDlo) (Figure 3.8 C lower panels), 
suggesting that the production or migration of B cell precursors from the bone 
marrow (BM) are reduced to a greater extent than B cell maturation..  
B220+ cells in the mutant BM were greatly reduced. In addition, among 
mutant B220+IgMlo cells, only 25.4 ± 4.1 % (n=4) were Pre-B (CD25hi), as 
compared to 82.9 ± 1.3 % (n=4) for littermate controls. This indicates a severe 
reduction in B cell precursors in Pfdn1 mutant mice (Figure 3.8 D). 
There appeared to be a higher percentage of TCR-beta positive T cells in 
mutant spleens, reflecting the relative lack of B cells. However, the percentages of 
CD4+ cells were significantly higher. The ratio of CD4+ to CD8+ T cells in 5 
mutant spleens was approximately 8 to 1, as compared to about 2 to 1 for WT and 
heterozygous littermates. Disproportionate numbers of CD4 T cells was also 
observed in the mutant thymus (Figure 3.8 E). Also strikingly, the percentage of 
CD4+CD8+ T cells was significantly lower in mutant thymus: 10.9 ± 3.1 % (n=5), 
than normal littermates: 77.7 ± 5.5 % (n=5). 
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 Figure 3.8. Pfdn1-/- lymphoid systems were defective. 
A.B. Hematoxylin and Eosin staining of spleen sections from Pfdn1+/+(A.)  
      and Pfdn1-/-(B.). GerminalCenter (GC).  
C. Reduction of B cells, especially T1 B cells in mutant spleen. Splenocytes from control 
littermates (left panel) and mutants (right panel) were analyzed for B220 and TCR-β
expression.  IgM/IgD expression of B220+ cells were analyzed in the following panels. 
IgMhiIgDlo cells were further analyzed for AA4.1 expression. T1:Transitional 1 B cells; 
T2: Transitional 2 B cells; M: Mature B cells; MZ: Marginal Zone B cells. 
D. Reduction of B220+ cells, especially Pre-B cells in mutant Bone Marrow. Bone 
Marrow cells from control littermates (left panel) and mutants (right panel) were 
analyzed for B220 and IgM expression. B220+IgMlo cells were further analyzed for 
CD25 expression. M: Mature circulating B cells; T: Transitional B cells; I: Immature B 
cells.  
E. Disproportion of T cell populations in mutant thymus. TCR positive cells were 
analyzed for CD4 and CD8 expression. 
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 In summary, loss of Pfdn1 function impairs development of major 
lymphoid organs, and reduces the number of lymphocytes in early developmental 
stages, especially pre-B cells and CD4+CD8+ T cells.  
 
Aberrant Actin cytoskeleton in Pfdn1-/- MEFs 
It is well established in yeast that proper cytoskeleton formation requires 
prefoldin.  Deletion of pfd5 in yeast, while not lethal, led to cytoskeletal 
alterations, as indicated by phalloidin staining morphological alterations and 
budding defects. (Vainberg, Lewis et al. 1998). 
Mouse Embryo Fibroblast lines were isolated to study the impact of Pfdn1 
mutation on a mammalian cytoskeleton. Cells from E13.5 embryos produced from 
Pfdn1+/- intercrosses were cultured at near-confluent densities and passed 1:2 
every two days. Pfdn1-/- MEF cells were viable, but appeared to grow more 
slowly than wild type cells.  The average time for the doubling of Pfdn1-/- MEFs 
at an initial number of 6x105 exceeded 4 days, as compared to 2-3 days for wild 
type and heterozygous MEFs.  Unlike conventional fibroblasts cultured.  Pfdn1-/- 
MEFs appeared to be round and flat in shape (Figure 3.9). 
.
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 Figure 3.9 Actin filaments in Pfdn1+/+ MEFs(A.) and Pfdn1-/-MEFs(B.). 
Wild type and Pfdn1 null MEFs were fixed, permeablized and stained with 
Alexa 594- phalloidin. The stained actin filaments in null cells appeared to be 
slimmer, shorter and less organized than those in wild type cells.  
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  Phalloidin staining revealed abnormal actin filaments (F-actin) in Pfdn1-/- 
MEFs (Figure 3.9 B). F-actins in Pfdn1 null cells were apparently shorter and less 
organized than in wild type cells.  Moreover, instead of spreading throughout the 
cell actin filaments were mostly localized to the periphery of Pfdn1-deficient 
cells.  Finally Pfdn1-/- cells contained cytoplasmic phalloidin-stained speckles.  
The abnormal localization and poor organization of F-actin is consistent with the 
phenotype of mutant yeast lacking prefoldin function (Vainberg, Lewis et al. 
1998).  Some defects in pfd5Δ yeast, such as impaired nuclear division in a small 
proportion of cells, were not observed in the established Pfdn1 null MEFs, 
however, nuclear division defects were not examined during the process of cell 
establishment.   
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 Discussion 
 
Mutagenicity of GTR1.3 polyA trap 
 PolyA gene traps preferentially insert into the last intron of cellular genes, 
(REFs),  which in some cases may fail to disrupt gene expression.  However, the 
insertion of GTR1.3 in the last intron of Pfdn1 completely ablated the Pfdn1 
expression as indicated by Western blot analysis. Although fusion transcripts 
containing Pfdn1 upstream exons were present at low levels, fusion proteins  
expressed from these transcript were not detected. 
 
Pfdn1 is not an essential gene 
Previous studies have established the important role of prefoldin in the 
maturation of essential proteins such as actin and tubulin (Vainberg, Lewis et al. 
1998; Hansen, Cowan et al. 1999; Siegert, Leroux et al. 2000; Martin-Benito, 
Boskovic et al. 2002; Siegers, Bolter et al. 2003). Considering the cytoskeletal 
defects caused by deletion of a  yeast  pfd  gene (Vainberg, Lewis et al. 1998) 
mouse Pfdn1 is surprisingly not an essential gene.  The complete deletion of 
Pfdn1 function did not result in embryonic death or obvious defects in organs 
such as heart, lung, liver, kidney, gut, eye, tooth, bone and muscle. Apparently, 
the basic cellular functions of the cytoskeleton such as cell division, cell shape 
maintenance, intracellular trafficking, etc. were not severely impaired. 
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Neuronal defects in Pfdn1 deficient mice 
The pathogenesis of several neurodegenerative diseases, including 
Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS), giant axonal 
neuropathy, Corticobasal degeneration and parkinsonism linked to chromosome 
17, have been linked to abnormal aggregation of cytoskeletal proteins. (REFs) 
Similarly the neuronal deficiencies in Pfdn1 -/- mice could  result from toxic 
effects of aggregated proteins that depend on Pfdn1 for proper folding.  However, 
cells affected by Pfdn1 deficiency, localized in the major Commissures were  
more limited than those affected by the common neurodegenative diseases.  
Similar commissure defects have been reported in deficient mouse models of 
genes regulating axon guidance, such as netrin and vax 1 (Serafini, Colamarino et 
al. 1996; Hallonet, Hollemann et al. 1998; Bertuzzi, Hindges et al. 1999; Deiner 
and Sretavan 1999; Kwon, Tsai et al. 1999).  However, the defects were not 
identical and the underlying mechanism may differ.  Instead of acting as a specific 
regulator of neuron specific activity such as axon guidance, Pfdn1 and/or its 
folding substrates are more likely to be involved through cytoskeleton 
reassembly.  Efficient assembly and disassembly of actin cytoskeletons are 
required for the structure and motility of the growth cone involved in axon 
outgrowth and possibly for synapse formation (Allen, Shan et al. 2000; Jay 2000; 
Kuhn, Meberg et al. 2000). As in yeast, lack of prefoldin function may reduce the 
maturation rate of actin, although not the amount of native actin.  In principles, 
the consequences of inefficient actin assembly would be magnified in rapidly 
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growing neuron filaments resulting in commissure defects  (Dent and Gertler 
2003); (Siegers, Waldmann et al. 1999).  
 
Lymphocyte development and cytoskeleton 
The deficient lymphopoeisis in Pfdn1-/- mice, in particular the reduction 
of pre-B cells in the bone marrow and of CD4+CD8+ T cells in the thymus appear 
to be caused by defects in the genesis and/or renewal of lymphocyte precursors, 
rather than blockages at later developmental stages.  Increasing evidence indicate 
a role for the actin cytoskeleton in immunological synapse formation.  For 
example, T cell activation is defective in mice lacking the Wiskott-Aldrich 
syndrome protein (WASP) (Snapper, Rosen et al. 1998). It is now well 
established that WASP, when recruited to activated T cell receptor (TCR), 
interacts with the Arp2/3 (Actin related protein 2 and 3) complex to regulate  
cytoskeletal reorganization of.  Rapid actin polymerization provides motile force 
for clustering of T-cell receptors to form a synapse, while the network of actin 
filaments provides a scaffold for sustained cell signaling  (Dustin and Cooper 
2000)).  
 
Cellular function of Pfdn1 indicated by deficient MEFs 
 Pfdn1-/- MEFs were  viable, but grew more slowly and were harder to 
establish as cell lines than wild type MEFs. Higher amounts of actin were 
detected in lysates of some  early passage Pfdn1 -/- MEFs.  However, these null 
cell strains failed to become immortalized cell lines and the actin over-expression 
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was not observed in any established mutant cell lines. Thus while actin 
overexpression is not an intrinsic trait of mutant cells it is possible that the 
increased expression is a compensatory response to reduced levels of properly 
folded protein. This may result in even higher levels of proteins aggregation and 
toxicity that would select against cell expressing higher levels of the protein. 
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Materials and Methods 
 
PolyA gene trapping 
The construction of GTR1.3 retrovirus and polyA gene trap library, as 
well as the analysis of 3’RACE products, are described elsewhere  (Lin et al. ( Lin 
et al. submitted).   
Sequences flanking one integrated provirus were isolated by inverse PCR. 
Briefly, 50-200 ng of genomic DNA from mouse tails was digested in 30 μl of 
digestion buffer with 5 units of AvaII (NEB). After overnight digestion at 37 °C, 
the reaction was terminated by incubation at 65°C for 10 min.  Subsequently  15 
μl of the digestion mix was ligated in a 20 μl reaction (T4 DNA ligase and buffer 
with 1mM ATP (NEB)) at room temperature for 10 min. 2μl of the ligation 
product was amplified by PCR in a 50 μl reaction (Roche) with primers: 
 Dp: CAGTCCTCCGATTGACTGAG and Up: GGGGTTGTGGGCTCTTTAT.  
The amplification involved 35 cycles of incubation at 94°C for 1 min, 55°C for 1 
min and 72 °C for 1 min. 
 
PCR Genotyping 
Mice and cells were genotyped by PCR as follows: 20-50 ng of genomic 
DNA was used as template in a 50μl reaction using the Roche PCR mix with 
primers: 
Dg: TGGGATAATGCCCACAGGTA, Ug: AAGCACTCAGAGCAGCAAGTT, 
and Dp: CAGTCCTCCGATTGACTGAG. 
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The amplification involved 30 cycles of incubation at 94°C for 1 min, 55°C for 1 
min and 72 °C for 1 min. 
 
Histological analyses 
 Samples were fixed in 4 % paraformaldehyde embedded in paraffin and 
10 μm serial sections were stained with hematoxylin and eosin. 
 
Cell culture and staining 
 Embryos at E13.5 were isolated, minced and treated with 2.5% typsin-
EDTA (Gibco BRL).  Cell suspensions were washed and cultured in DMEM 
(Meditech), supplemented with 10% fetal calf serum (heat inactivated at 55oC  for 
30 min) and 100 U/ml of penicillin-streptomycin (Gibco BRL).  The primary 
MEFs were cultured at nearly confluent densities and passed at a 1:2 ratio until 
cell lines were obtained.  MEFs were stained with alexa594-phalloidin as 
elsewhere described (Weaver lab staining paper) 
 
Analysis of Pfdn1 gene expression 
 The expression of Pfdn1 on mRNA transcripts in mice and cells was 
assessed by Northern blot hybridization to a [32P]dCTP-labled probe derived from 
the full length Pfdn1 cDNA, as described previously (Williamson, Banik-Maiti et 
al. 2000).  
 Prefoldin 1 protein expression in ES cell clones was assessed by Western 
blot analysis.  Cell lysates were fractionated by electrophoresis on a 12% SDS-
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polyacrylamide gel and transferred onto a PVDF membrane (NEN life science), 
Prefoldin 1 proteins were detected by using donkey polyclonal antibodies raised 
against an internal region of the protein (San Cruz Biotechnology), as described 
previously (Williamson, Banik-Maiti et al. 2000). 
 
Peripheral blood analyses and FACS 
 Peripheral blood samples were applied to glass slides and stained with 
Wrights stain.  Whole blood cell counts were obtained on a Coulter counter.  
Single-cell suspensions were prepared from lymphoid organs and stained with 
fluorescent antibodies (BD bioscience Pharmingen) following standard protocols. 
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CHAPTER IV  
 
SUMMARY AND FUTURE PERSPECTIVES 
 
Summary 
My thesis work has been focused on characterizing the phenotypes of 
Ssrp1 and Pfdn1 deficient mice, generated by gene targeting and gene entrapment, 
respectively.  
Prior to my study, SSRP1 has been implicated in V(D)J recombination 
(Shirakata, Huppi et al. 1991) and cell responses to DNA damage (Bruhn, Pil et 
al. 1992), while these two processes are not mutually exclusive, as illustrated by 
Ku70, Ku80, Lig4, and XRCC4, proteins involved in Non-homologous end 
joining (NHEJ) (Frank, Sharpless et al. 2000; Gao, Ferguson et al. 2000; Nick 
McElhinny, Snowden et al. 2000; Gellert 2002). In order to delineate the in vivo 
function of Ssrp1, especially its role in V(D)J recombination and DNA repair, 
Ssrp1 was targeted via homologous recombination and the mutation was 
introduced into the germline. Targeting of Ssrp1 disrupted the expression of the 
gene, lead to embryonic death shortly after implantation and the ex vivo death of 
Inner Cell Mass (ICM), indicating that Ssrp1 is required for the growth and/or 
survival of pluripotent cells in early embryos. Apoptosis did not appear to be the 
major mechanism of early embryonic death. Moreover, loss of p53 did not rescue 
lethality of Ssrp1 mutant embryos and cells, unlike genes involved in DNA repair 
or NHEJ. Ssrp1 appears to encode non-redundant and p53-independent functions 
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that are necessary for cell viability, unlike a number of proteins involved in DNA 
repair.  In subsequent studies, SSRP1 was identified as a component of a 
chromatin remodeling complex, FACT, that is involved in DNA replication, 
transcription elongation (Okuhara, Ohta et al. 1999; Belotserkovskaya, Oh et al. 
2003; Kaplan, Laprade et al. 2003; Saunders, Werner et al. 2003). Moreover, 
Pob3, the yeast SSRP1 ortholog, is required for cell viability (Wittmeyer and 
Formosa 1997). Temperature sensitive (Ts) mutations in Pob3 produce 
phenotypes similar to histone mutations (Wittmeyer and Formosa 1997), 
implicating SSRP1 involved in the global maintenance of chromatin structure. In 
general, these observations were consistent with my results, indicating that Ssrp1 
encode non-redundant functions that play essential roles in cellular metabolism.  
Another part of my thesis research started from the gene entrapment of 
Pfdn1 gene by a Pfdn1 encodes the first subunit of molecular chaperone prefoldin, 
which assists the folding of cytoskeletal proteins such as actin and tubulin 
(Vainberg, Lewis et al. 1998; Hartl and Hayer-Hartl 2002). Deletion of one or all 
of the six prefoldin genes in yeast, does not affect the cell viability, but reduces 
the rate of actin maturation, and leads to impaired cytoskeletal assembly and 
function  (Vainberg, Lewis et al. 1998). To understand the function of Pfdn1 in 
mammalian cells, and more importantly, the impact of potential cytoskeletal 
defects on various cell types in mice, an ES clone containing mutated Pfdn1 was 
identified from the gene trap library and transmitted into the germline. Insertion 
of the entrapment vector in the last intron of Pfdn1 ablated expression of the gene. 
Pfdn1 -/- mice were born at nearly Mendelian ratios, but most died before 5 
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weeks of age, after a period of stunted growth, physical wasting and 
neuromuscular dysfunction. Postnatal phenotypes of Pfdn1 -/- mice include: (1) 
CNS defects involving the corpus callosum (CC) and cerebellar commissure 
(cbc); (2) hematopoietic defects consisting of micronucleated erythrocytes and 
neutrophils with abnormal nuclear segmentation; and (3) compromised immune 
systems with loss of B and T lymphocyte precursors. The organization and 
reassembly of actin cytoskeleton were impaired in Pfdn1 -/- MEFs and B 
lymphocytes. These results suggest that Pfdn1 encodes non-redundant, tissue-
specific functions required for mouse development and survival, presumably by 
affecting cytoskeleton formation.  
  With the sequence of the human and mouse genomes the task of gene 
identification is largely complete.  The focus now shifts to understanding gene 
function, both in the context of the whole organism and as a component of 
biochemical pathways.  The problem has prompted efforts to disrupt all genes via 
the Knockout Mouse Project.  The goal is to create null mutations in all genes 
either by gene targeting or by gene entrapment.   
   While my study included only two genes disrupted by gene targeting and 
gene entrapment, it provides certain perspectives for the methodology of 
functional genomics.  
  Gene targeting by gene targeting has the advantage of creating exactly the 
desired mutation.  Thus the targeted mutation in Ssrp1 deletes the 3’ exams of one 
functionally essential HMG box.  While entrapment mutations are less 
predictable, one insert in Pfdn1 also appeared to cause a null mutation.  However 
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gene targeting is fare more labor intensive and expensive thus we were able to 
target nearly 1000 genes in ES cells in less time and at a cost significantly lower 
than the cost of disrupting SSRPl. 
 Given the hours and expense gene targeting is best reserved for genes 
about which much is already known and where the mutation is likely to provide 
biological insights on gene function.  However, predictions are frequently 
inaccurate.  For example, cellular lethality of Ssrp1 deficiency produced further 
studies on the in vivo functions of Ssrp1 and biochemical analysis of SSRP1 
deficient cells.  Conversely given the known role of Pfdn1 in actin folding in 
yeast made the gene a poor candidate for gene targeting.  However the phenotype 
of Pfdn1-deficient mice predicts a novel role for the cytoskeleton in lymphocyte 
development. 
 Whether generated by gene entrapment or gene targeting the analysis of 
null mutations will identify genes that would benefit from conditional 
mutagenesis.   Conditional gene targeting, via temporal or tissue-specific deletion 
of the  target gene, is a powerful means to bypass and to dissect the role of the 
targeted gene in specific developmental periods or in specific cells or tissues. 
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Future Perspectives 
 My current studies on Pfdn1 deficient mice suggested some of the 
essential functions of Pfdn1 in tissues/systems that require Pfdn1 the most. This 
preliminary characterization raises a number of questions to be addressed by 
future studies that take advantage of the knockout mouse model described in this 
dissertation. 
The first category of future studies will be the biochemical analysis of 
protein folding in Pfdn1 deficient cell lines. In yeast lacking one or more 
prefoldin/Gim genes, the maturation rate of actin is reduced, as assessed by the 
specific binding of DNaseI to native actin monomers (Siegers, Waldmann et al. 
1999). It follows naturally to assess the folding rate of actin in Pfdn1 deficient 
mammalian cells. Although very likely there will be a reduction, as suggested by 
the “downstream” cytoskeletal defects, how exactly the kinetics are affected will 
provide insight into how Pfdn1 deficiency impacts the cytoskeleton. For example, 
if the reduction is less than that of mutant yeast, this may provide potential 
explanation to why not all cell types were affected and why the homozygous 
mutants were born alive. Additionally, since it is not yet certain whether 
disrupting Pfdn1 also ablates the functions and/or structure of the prefoldin 
complex, comparing actin folding rates is one of the functional assays that will 
shed light on this question. As an experiment, RNA interference may be used to 
knockdown the expression of Pfdn5, which encode a subunit required for the 
prefoldin complex formation. Actin folding rates will be compared in a panel of 
cells, with Pfdn1 deficiency and/or Pfdn5 knockdown. The cell line(s) that 
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provides the lowest actin maturation rate potentially has the lowest or no function 
of prefoldin complex. If the Pfdn1 deficient cell line has an intermediate rate, it is 
very likely that disruption of Pfdn1 does not completely abolish the function of 
prefoldin complex. 
Other than actin, folding of tubulin is known to require prefoldin. In 
addition, there are known substrates for TRiC complex, including proteins related 
to cytoskeleton, such as actin-related protein V, cofilin and actin-depolymerizing 
factor 1 (Frydman, Nimmesgern et al. 1992; Gao, Thomas et al. 1992; Melki, 
Vainberg et al. 1993; Ursic, Sedbrook et al. 1994; Melki, Batelier et al. 1997), all 
candidate substrates of prefoldin. The list of candidates may expand, even beyond 
the category of proteins related to cytoskeleton. For example, expression of Pax5, 
a regulator of B lymphocyte development, is correlated with Pfdn1 in the brains 
of recombinant inbred mouse strains (refer to www.webqtl.org). Moreover, Pax5 
deficient mice have phenotypes similar to Pfdn1 deficiency. Mice lacking of Pax5 
are also born at close to Mendalian ratio, with retarded growth in all and early 
death in some of them. Moreover, Pax5 deficient mice defects are also largely 
restricted in the Central Nervous System and B lymphocyte development, 
although defect patterns are not the same as that of Pfdn1 deficiency (Urbanek, 
Wang et al. 1994). Pax5 is an example of immune/neuron specific regulators that 
might be substrates of prefoldin, and when unfolded, contribute to the defects in 
immune system and CNS in Pfdn1 deficient mice. 
As mentioned above the composition of prefoldin complexes has not be 
characterized in cells lacking Pfdn1, which is not required for formation of 
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prefoldin heterohexamer (Martin-Benito, Boskovic et al. 2002). For example the 
remaining 5 prefoldin subunits form complexes could with chaperonin activity. 
This possibility could be examined by Western blot analysis of prefoldin 
complexes fractionated on non-denaturing gels probed with antibodies against 
prefoldin 2 or 5, the two subunits required for complex formation.  Multimeric 
prefoldins are expected to migrate with apparent molecular weights greater than 
the 30 kDa monomer. Further, actin folding activity can be measured using the 
DNaseI- actin binding assay, and the composition of the complexes can be 
assessed western blotting. It is intriguing whether multimeric prefoldin complexes 
can form in the absence of Pfdn1, or whether other subunits can substitute for 
Pfdn1 in the hexameric complex. 
The lymphopoiesis defect in Pfdn1 deficient mice was marked by the loss 
of B and T lymphocytes, especially the precursor cells. However, it remains 
unknown whether the lymphocyte defects are cell autonomous or environment-
related.   The proliferation and function of Pfdn1 deficient lymphocytes in a 
mouse following transfer of mutant bone marrow into irradiated recipients.  After 
2~4 weeks of recovery, lymphocytes in the recipient mouse are derived from the 
transferred bone marrow cells.  If lymphocytes defects in mice grafted with 
mutant lymphocytes would suggest that the lymphocyte defects are cell 
autonomous. If there is only mild or no difference, it is likely that the environment 
of Pfdn1-deficient mice contributes to the lymphocyte defects. Considering that 
loss of precursor cells is more severe than loss of mature lymphocytes in Pfdn1 
deficient cells, the lymphocyte defects are more likely to be cell autonomous. 
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The assembly and function of actin filaments were defective in Pfdn1 
deficient cells. Although the actin cytoskeleton defect might be the major cause of 
the immune comprised phenotype, it does not rule out possibilities of unfolded 
immune specific regulators that are substrates of prefoldin. One candidate 
substrate, Pax5 was discussed earlier in this chapter. Future studies on defective 
lymphocytes from Pfdn1 deficient mice will address how actin cytoskeleton 
defects affect immune synapse formation and/or cell-cell interaction, and how 
these processes in turn affect the development and function of lymphocytes. 
The commissure defects in Pfdn1 deficient mice should lead to more 
detailed studies on the development of Pfdn1 deficient neurons. Growth and 
orientation of an axon rely on rapid, organized assembly and disassembly of actin 
cytoskeleton in the growth cone (Jay 2000; Kuhn, Meberg et al. 2000). Axon 
outgrowth of a Pfdn1 deficient neuron can be studied in in vitro cell cultures. The 
defective structure and/or function of actin cytoskeleton in the growth cone may 
contribute to the aberrant formation of the axon of Pfdn1 deficient neurons. This 
may underlie why brain commissures, essentially bundles of neural fibers, were 
severely affected in Pfdn1 deficient mice. 
The commissure defect in Pfdn1 deficient mice, was similar to netrin-1, 
DCC, vax1, p35 (Serafini, Colamarino et al. 1996; Hallonet, Hollemann et al. 
1998; Bertuzzi, Hindges et al. 1999; Deiner and Sretavan 1999; Kwon, Tsai et al. 
1999). However, the commissure in Pfdn1 deficient mice was unique in that 
apparent cell death is involved. Future studies should probe the possible 
involvement of surrounding cells, such as glia cells. A defective cell-cell 
 91
interaction could trigger death of neurons. If the death is cell autonomous, there 
are three potential mechanisms: 
1. Loss of Pfdn1 leads to reduced levels of native actin monomers. The 
phenotype is reflected in cells that require rapid cytoskeleton assembly and 
reassembly. 
2. Pfdn1 deficiency may lead to a toxic accumulation of unfolded proteins, 
and some cells are more sensitive to this toxicity. 
3. While prefoldin complexes are ubiquitous, some cells rely on the 
specific functions of prefoldin 1, and are more severely affected by the loss of 
Pfdn1. 
While not mutually exclusive, these hypotheses could address the cell 
death of brain commissures, as well as defective hematopoiesis and 
lymphopoiesis. Future studies should test these three hypotheses. 
 In summary, Pfdn1 deficient mouse provides a genetic model to study the 
in vivo functions of the prefoldin complex or subunit 1. The neuronal, 
lymphopoietic defects revealed in my studies would be a start point for future 
studies on the role of prefoldin in cytoskeleton formation, in the context of 
development and function of neuron and immune systems.  
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